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As many as 87% of children discontinue ADHD medication, which can lead to clinically 
significant academic, cognitive, and social impairment.  ADHD costs billions of dollars 
to the healthcare and educational systems, and previous attempts to stem these costs and 
increase ADHD medication adherence have been unsuccessful.  The purpose of this study 
was to determine if patient-centered medical homes (PCMH), which have been shown to 
improve patient health outcomes, impact parental beliefs (benefits vs. risks) about ADHD 
medication and adherence to ADHD medication.  The theory of planned behavior was the 
theoretical framework for this study.  There were 294 parents of children between the 
ages of 5 and 12 who had been prescribed ADHD medication who participated in a 
quantitative self-administered survey.  Parental beliefs were assessed using the Beliefs 
About Medicines Questionnaire–Specific, and medication adherence was assessed using 
the Morisky Medication Adherence Scale–8.  The 2007 National Survey of Children’s 
Health was used to determine group assignment.  A MANCOVA was used to analyze the 
data and found parents in the PCMH group scored significantly higher in their beliefs that 
the benefits outweighed the risks of ADHD medication.  However, no significant 
differences were found between groups related to parental adherence to ADHD 
medication.  More research is recommended to learn how PCMHs can change positive 
ADHD medication beliefs into better ADHD medication adherence. This study has social 
change implications as it increases what is known about PCMHs and how they impact 
health outcomes.  It also supports previous literature in the need to deliver all PCMH 
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Chapter 1: Introduction to the Study 
In this study I evaluated the impact of patient-centered medical homes (PCMHs) 
on parental beliefs about attention-deficit hyperactivity disorder (ADHD) medication and 
ADHD medication adherence. Adherence to medication is a critical element related to 
pharmacological effectiveness, and it is especially important for people with chronic 
conditions (Brown & Bussell, 2011).  Recent literature showed as many as 21% of 
children with ADHD stopped taking their medication during the first year, and of those 
children who discontinued, 75% stopped taking their medication within the first 3 months 
of initiating pharmacotherapy (Toomey, Sox, Rusinak, & Finkelstein, 2012).  The 
consequences of nonadherence to medication were an increased likelihood of social and 
academic impairment, substance use, unsafe driving, and decreased quality of life.  Adler 
and Nierenberg (2015) reported up to 64% of individuals are nonadherent to their ADHD 
medication and indicated nonadherence occured more frequently with the use of 
immediate release stimulant medications.  However, Ahmed and Aslani (2013) reported 
nonadherence to ADHD medication is as high as 87%. ADHD can lead to significant 
academic and social impairment, risky behaviors, and diminished quality of life.  
The PCMHs have been reported to improve health outcomes (Homer et al., 2008, 
Patient-Centered Primary Care Collaborative, 2015) and may decrease ADHD 
medication nonadherence among children.  Although there is a plethora of literature 
available on PCMHs and treatment outcomes (An, 2016; Brown & Bussell, 2011; 
Domino, Wells, & Morrissey, 2015; and DeVries et al., 2012), there is no current 




parental ADHD medication beliefs.  This study has positive social change implications as 
PCMHs demonstrated they increase parental beliefs about adherence to ADHD 
medication, which could lead to the increased parental adherence in the future.  This 
would potentially decrease the economic burden associated with increased healthcare and 
education resource utilization and improve the quality of life of children with ADHD.  
Additionally, this study extends the knowledge base of what is known about the impact 
of PCMHs on treatment outcomes, particularly as it relates to parental medication 
adherence and beliefs related to children with ADHD.  Finally, this research may impact 
healthcare policy created by agencies such as the Centers for Medicare and Medicaid and 
the American Academy of Pediatrics that support PCMH enrollment for children with 
ADHD and lead to increased patient access to PCMHs. 
In Chapter 1, I discuss the background of the study, the major areas of research 
related to the study, and the problem statement, and provide the research questions and 
hypotheses.  I elaborate on the theoretical framework and nature of the study in Chapters 
2 and 3.  I also discuss the study methodology, assumptions, scope and delimitations, and 
limitations. The chapter concludes with the significance of the study and a summary of 
the chapter. 
Background of the Study 
ADHD is a neurodevelopmental disorder that involves the inability to control 
impulsive behaviors and includes difficulty with paying attention (CDC, 2013).  Feldman 
and Reiff (2014) reported that ADHD is most prevalent in boys, with boys also having a 




disorder is generally diagnosed during childhood, however researchers have asserted it 
can also persist into adulthood (Feldman & Reiff, 2014). The Diagnostic and Statistical 
Manual of Mental Disorders–5 (DSM-5) required that no fewer than five symptoms be 
present in one or both domains prior to the age of 12 in order to receive an ADHD 
diagnosis (American Psychiatric Association, 2013).  At the point of diagnosis, treatment 
such as behavior therapy and/or pharmacotherapy is generally prescribed. 
Pharmacotherapy, particularly using stimulant medication, can be very effective 
and is first-line pharmacotherapy for the treatment of ADHD (Weyandt et al., 2014).  
Medication may provide children and adolescents with ADHD with a significant 
opportunity to achieve long-term treatment success, including improved academic 
performance, decreased deviant behavior related to poor peer and family relationships, 
and fewer unintended injuries, if they adhere to the treatment regimen (Chacko, 
Newcorn, Feirsen, & Uderman, 2010; McConaughy, Volpe, Antshel, Gordon, & Eiraldi, 
2011; Murray-Close et al., 2010; Klein et al., 2012).  Some side effects associated with 
pharmacotherapy include changes in mood and personality, depression, and irritability 
(Toomey et al., 2012). 
Members of the medical community have generally categorized medication 
adherence as patient related, medication related, and environment related (Ferrin & 
Taylor, 2011).  Key contributors to low medication adherence include parental attitudes 
about medication, presence of side effects, perceived effectiveness, age, gender, race, and 
socioeconomic status (SES; Brown & Bussell, 2011; Malaysia, 2010; Toomey et al., 




Brown and Bussell (2011) additionally reported that factors related to nonadherence of 
urban and low socioeconomic patients are high medication costs as well as problems with 
insurance and insurance coverage.  
Ferrin et al. (2012) reported there is a difference between nonintentional 
nonadherence and intentional nonadherence, stating factors such as low IQ, adverse 
effects, and challenging drug regimens contribute to nonintentional nonadherence, while 
environmental factors such as family or personal attitudes contribute to intentional 
nonadherence.  I focused this research more on intentional nonadherence to ADHD 
medication and how parental attitudes and beliefs may impact their adherence to ADHD 
medication in both PCMHs and non-PCMHs. 
Parental perceptions toward ADHD medication are important, as parents are the 
ones primarily responsible for making treatment and healthcare decisions for their 
children (Charach & Fernandez, 2013).  However, the amount of influence parents have 
on their child’s decisions regarding medication adherence often diminishes as the child 
ages (Chacko et al., 2010).  Chacko et al. (2010) further posited that both the parent’s and 
the child’s beliefs and attitudes around medication moderate medication adherence, 
although it is the parent’s understanding of ADHD that determines whether the child 
originally accepts stimulant medication.  It is important for practitioners to focus their 
efforts on helping parents understand ADHD, medication treatment options, and how 
their child may benefit from adhering to the prescribed treatment regimen.  Emphasis in 
this area could potentially reduce the economic burden on the healthcare system and 




The introduction of the PCMH in 1967 was designed to reduce resource 
utilization and to address some of the above issues that affect children with special health 
care needs (Sia, Tonniges, Osterhus, & Taba, 2004).  PCMHs are pediatric or primary 
care physician offices that approach care delivery through the provision of the following:  
(a) patient-centered care, which includes compassionate and culturally sensitive care; (b) 
comprehensive care, which includes services for mental health and chronic care; (c) 
coordinated care, which includes communication between multiple providers and 
services; (d) accessible care, which includes 24-hour, 7-day-a-week access to phone 
and/or electronic records; and (e) care that is committed to quality, which includes 
medication management (Patient-Centered Primary Care Collaborative, 2013).  Health 
care providers in PCMHs emphasize the patient as a whole and integrate other medical 
and pharmacy personnel into the decision-making process of patient care.  Additional 
services offered in a PCMH include medication review, coaching and advice, and peer 
support and encouragement to assist patients with their overall care experience.    
The passage of the Patient Protection and Affordable Care Act in 2010 mandated 
the implementation of PCMHs, which have been widely adopted throughout the United 
States (Fields, Leshen, & Patel, 2010).  Currently, there is no requirement for PCMHs to 
be accredited by any organization.  However the National Committee for Quality 
Assurance (NCQA; 2014) recognized over 10% of primary care practices in the United 
States as PCMHs.  The increase in support of PCMHs and accreditation by these 
organizations should lead to expansion of these types of medical practices, thus providing 




also prove to be an important way to address poor medication adherence in children with 
ADHD, as there is no current literature that speaks to the impact of PCMHs on parental 
beliefs about ADHD medication and parental medication adherence in this population.  
This research may demonstrate that PCMHs improve parental attitudes and adherence to 
ADHD medication and thus provide an effective model to improve patient outcomes and 
decrease the health-related, academic, and social costs associated with ADHD. 
Problem Statement 
ADHD can lead to clinically significant academic impairment (e.g., low 
standardized testing scores), decreased cognitive ability (e.g., low scores on full-scale IQ 
testing), social impairment (e.g. poor family and peer relationships; Bussing, et al., 2012; 
Express Scripts, 2014; McConaughy et al., 2011; Visser et al., 2014), an increased 
occurrence of grade retention and failure to graduate (Robb et al., 2011), increased 
emergency room visits, unintended injuries (Merrill, Lyon, Baker, & Gren, 2009; 
Schwebel et al., 2011), parenthood at an early age (Barkley, Fischer, Smallish, & 
Fletcher, 2006; Reimer, Mehler, D’Ambrosio, & Fried, 2010), poor peer and family 
relationships that can lead to delinquent behavior, and greater likelihood to have 
substance use disorder (Klassen, Miller, & Fine, 2004; Wilens et al. 2011).  Additionally, 
because ADHD can persist into adulthood, poorly managed ADHD symptoms can 
adversely impact gainful employment due to the poor development of social skills 





Medication may provide children and adolescents diagnosed with ADHD with a 
significant opportunity to achieve long-term treatment success through symptom 
management, including impulse control, increased concentration, decreased aggression, 
and reduced hyperactivity and social withdrawal (Nijmeijer et al., 2008, Prasad et al., 
2013) if they adhere to the treatment regimen (Chacko et al., 2010).  Reasons attributed to 
medication adherence are patient-related (e.g. SES; Brown & Bussell, 2011), medication-
related (e.g., efficacy; Barner, Khoza, & Oladapo, 2011), and environment-related (e.g., 
parental beliefs; Ferrin & Taylor, 2011, Garbe et al., 2012; Zetterqvist, Asherson, 
Halldner, Långström, & Larsson, 2013).  Dawood, Isham, Ibrahim, and Palaian (2010) 
contended that for those children with chronic illness, the lack of parental understanding 
of their child’s illness, reticence around therapy efficacy, and concern about adverse 
effects of medication impact children’s adherence. Thus, parents have the largest impact 
on their child’s medication initiation and adherence (Bai, Wang, Yang, & Niu, 2015). 
Attempts to increase medication adherence include enhancing parental knowledge 
and information regarding ADHD, educating parents on the safety and the social 
acceptability of medication, behavior therapy, and psychoeducation (Bussing et al., 
2012).  The literature reveals that while some of these interventions (psychoeducation 
and behavior therapy) may have some incremental impact on increased medication 
adherence in the short term, substantial increases in medication adherence remain a 
challenge (Dean, Walters, & Hall, 2010; Hébert, Polotskaia, Joober, & Grizenko, 2013, 
Sitholey, Agarwal, & Chamoli, 2011).  Methods to reduce the economic loss, social 




adherence is of significant importance to healthcare professionals and researchers 
(Bussing, et al., 2012, Lehmann et al., 2014, Schwebel et al., 2011). 
Brown and Bussell (2011) suggest that PCMHs should contribute to increased 
medication adherence due to the type of patient-centered care delivered in a PCMH.  
However, parental beliefs and attitudes can be a barrier to adherence and persistence.  
Corkum, Bessey, McGonnell and Dorbeck (2015) argue parental perceptions of ADHD 
as well as their acceptability of treatment options are the central barriers to medication 
adherence.  Researchers found when parents are provided with relevant information 
around ADHD treatment, adherence to medication can be increased (Bai et al., 2015; 
Corkum, Rimer, & Schachar, 1999).  Current research indicates lack of knowledge about 
ADHD and its treatment and poor emotional support are the primary obstacles for 
medication initiation and persistence (Bai et al., 2015).   
PCMHs have been shown to reduce pediatric resource utilization (DeVries et al., 
2012) and place emphasis on the patient as a whole.  PCMHs also integrate other medical 
and pharmacy personnel into the decision-making process of patient care and offer 
services such as medication review, coaching and advice, and peer support and 
encouragement to patients, which assist with their overall care experience.  PCMHs can 
provide improvements to health outcomes for those children with challenging medical 
conditions such as ADHD, where care coordination is recommended (Knapp et al., 2012).  
Fragmented health care, such as poor care coordination, limited access to care, limited 
amount of time available for providers to spend with the patients, and inadequate 




medication adherence (Brown & Bussell, 2011; Croghan & Brown, 2010).  Knapp et al. 
(2013) asserted that PCMHs are critical for children with mental health conditions, which 
can impact the entire family. Toomey, Homer, and Finkelstein (2010) not only found 
disparities related to the diagnosis and treatment of children with mental health disorders, 
they also reported disparities between mental health disorders and medical home 
attainment.  The investigators found the likelihood of children with ADHD to have a 
PCMH was lower than that of children with asthma; which is a chronic medical 
condition.  This finding indicates children with mental health conditions, such as ADHD, 
may be missing out on the benefits of PCMHs and the potential for improved outcomes.  
Therefore, PCMHs were evaluated in this study to assess their influence on parental 
beliefs about ADHD medication (benefits vs. risks) and their adherence to ADHD 
medication.   
Purpose of the Study 
The purpose of this quantitative study was to determine if PCMHs have a 
significant impact on parental beliefs related to ADHD medication and parental ADHD 
medication adherence.  To address this gap, I conducted a quantitative study to survey 
parents of children with ADHD who do and do not have a PCMH and assess parental 
beliefs regarding ADHD medication (risks vs. benefits) and their adherence to prescribed 
ADHD medication.  I utilized questions from 2007 National Survey of Children’s Health 
(NSCH; Toomey, Chan, Ratner, & Schuster, 2011) to determine what type of provider 
the parent has chosen for their child’s care (PCMH or non-PCMH).  The Beliefs About 




Medication Adherence Scale (MMAS–8; Morisky, Ang, Krousel-Wood & Ward, 2008)) 
were utilized in this study to assess parental beliefs about ADHD medication and their 
adherence to ADHD to medication.  The following covariates were evaluated for 
inclusion in the study: age, ethnicity, gender, SES, education, geographic location, and 
parent’s own experience with taking ADHD medication. 
Research Questions and Hypothesis 
RQ1: Is there a difference in parental beliefs about ADHD medications (benefits 
vs. risks) as measured by the BMQ–Specific between PCMH and non- PCMH 
groups?  
H01: There is no significant difference in parental beliefs about ADHD 
medication (benefits vs. risks) between PCMH and non-PCMH groups. 
Ha1: There is a significant difference in parental beliefs about ADHD 
medication (benefits vs. risks) between PCMH and non-PCMH groups. 
RQ2: Is there a difference in parental adherence to ADHD medication as 
measured by the MMAS–8, between PCMHs and non-PCMH groups? 
H02: There is no significant difference in parental adherence to ADHD 
medication between PCMH and non-PCMH groups. 
Ha2: There is a significant difference in parental adherence to ADHD 
medication between PCMH and non-PCMH groups. 
Theoretical Framework 
I used the theory of planned behavior (TPB; Ajzen, 1991) as a theoretical 




treatment directly impact their children’s medication-taking behavior.  When parents 
perceive there are positive psychosocial benefits to stimulant medication, their children 
also perceive greater psychosocial benefits to medication (Hebert et al. 2013). This may 
impact children’s beliefs around ADHD medication, which have been shown to directly 
impact how they choose to manage their illness (Ferrin & Taylor, 2011).   
I used the TPB, an extension of the theory of reasoned action (Fishbein & Ajzen, 
1975), to better understand parent’s beliefs and attitudes toward ADHD and how those 
beliefs may impact their child’s intention to adhere to medication.  The theory asserts the 
intention of a person to perform a specific behavior is a reflection of the motivational 
influences on that behavior (Ajzen, 1991).  The three components that influence 
behavioral intention are:  a) attitude, b) subjective norm, and c) perceived behavioral 
control.  Ajzen (1991) posits that the stronger a person’s intention to engage in a 
behavior, the higher the probability that the behavior will occur.  Subjective norms are 
indicative of a person’s beliefs related to how individuals in their social network perceive 
the behavior in question.  A person’s belief in their ability is referred to as their perceived 
behavioral control (Azjen, 1991).  Therefore, the more positive a person’s attitude and 
subjective norm, the greater that person’s perceived control and the higher the likelihood 
of the person’s intention to perform the targeted behavior.  This theory helped to explain 
the effectiveness of PCMH’s to impact parental beliefs and attitudes around ADHD and 
it’s treatment, which can lead to positive medication-taking intention of their children.  
This theory helped to provide context for the research questions from the BMQ–Specific, 




linked to behavioral intention.  It also provides context for the MMAS–8, which queries 
parent’s actual adherence to ADHD medication for their children and is the targeted 
behavior for this research. 
Several other theories have been used in the literature to explain medication 
taking behavior that were considered for this study:  the illness career model (Biddle, 
Donovan, Sharp, & Gunnell, 2007), the trans-theoretical model of change (Prochaska & 
DiClemente, 1984), the health belief model (Hochbaum, Rosenstock, & Kegels, 1952), 
social exchange theory (Hamrin, McCarthy, & Tyson, 2010), and the unified theory of 
behavior change (UTB; Jaccard, Dodge, & Dittus, 2002).  Each of these theories suggests 
different factors that contribute to medication adherence; however, the TPB was the best 
fit for this research.  I discuss the theoretical framework further in Chapter 2. 
Nature of Study 
The nature of this study was quantitative and utilized a self-report survey 
administered via Qualtrics to determine if PCHMs influenced parental beliefs about 
ADHD medication (benefits vs. risks) and their adherence to ADHD medication.  I chose 
this design because only a quantitative design can test statistical differences between 
groups.  I had one subject variable (PCMH) and two dependent variables (parental beliefs 
about ADHD medication and parental ADHD medication adherence). A multivariate 
analysis of variance (MANOVA) was used to analyze the data using the SPSS 24.0 
software package.  A quantitative survey was the most effective method to obtain this 
data because it allowed me to capture data from a large representative sample of parents 




anonymous.  The target population was parents with children between the ages of 5 and 
12 who had been diagnosed with ADHD and who had been prescribed ADHD 
medication for at least three months.  This age range was selected because parents are 
largely responsible for administering medication to their children up to age 12.  As 
children age, they tend to have more influence on their own medication taking behavior.  
Prior to age 5, behavior therapy is recommended as the first-line approach according to 
the American Academy of Pediatrics.   
Definition of Terms 
Medication adherence: The degree to which a person’s behavior matches the 
agreed recommendations from a health care practitioner, including following diet and 
lifestyle changes as well as taking medication (World Health Organization, 2003).   
Patient-centered medical home (PCMH): A pediatrician’s or primary care 
provider’s office that provides the following care components: (a) patient-centered care, 
(b) comprehensive care, (c) coordinated care, (d) accessible care, and (e) commitment to 
quality and safety (Patient-Centered Primary Care Collaborative, 2015).   
Benefits: Refers to necessity as described in the BMQ–Specific scale. 
Risks:  Refers to concerns as described in the BMQ–Specific scale. 
Attention deficit/hyperactivity disorder (ADHD): A continued pattern of 
hyperactivity-impulsivity and/or inattention that impedes a person’s ability to function or 
develop, with symptoms that present in at least two settings (e.g. school, home, with 




Multiple symptoms must be evident before the age of 12 (American Psychiatric 
Association, 2013).  
Assumptions 
This study was based on several assumptions.  Firstly, I assumed that the parents 
who participated in the survey would answer the questions honestly and accurately.  
Secondly, I assumed the questions from the BMQ, which were used to assess parent’s 
beliefs and attitudes around ADHD, were a valid and reliable measure of parental beliefs 
and attitudes.  Thirdly, I assumed the questions utilized from the MMAS-8, which were 
used to assess parents’ adherence to ADHD to medication, were a valid and reliable 
measure of children’s intention to adhere to medication.  Additionally, I assumed that the 
parent’s responses accurately reflected their beliefs about ADHD medication and their 
adherence to their child’s prescribed ADHD medication.  I also assumed that the parent’s 
responses to the questions from the 2007 NSCH survey accurately depicted the type of 
medical provider they utilized for their child’s healthcare.  Lastly, I assumed that the 
survey participants reflected an ample sample size for both parents with a PCMH and 
parents without a PCMH.  The above assumptions increased the study reliability and 
external validity.  In the following section I discuss the scope and delimitations of the 
study. 
Scope and Delimitations 
The scope of this quasi-experimental research included parental responses to 
survey questions related whether or not they utilized a PCMH for their child’s healthcare, 




parent’s responses to questions related to their adherence to their child’s ADHD 
medication.  To be included in the survey, parents must have had a child with ADHD, 
between the ages of 5 and 12 for whom ADHD medication had been prescribed for the 
previous 3 months.  Potential generalizability may be impacted based on the variation in 
the sample of parents on the demographic variables in both groups. 
I utilized the TPB, which was the theoretical framework for this study, to provide 
context to the two research questions around parental beliefs and attitudes and the 
influence of these beliefs on the parent’s adherence to medication.  The TPB also served 
as the basis to analyze the survey results and represented the motivational influences that 
impacted the parent’s intention to follow the medication-taking regimen prescribed by a 
healthcare practitioner.  
I chose the focus of this study because it could possibly demonstrate that PCMHs 
positively impact parental beliefs/attitudes related to ADHD medication and improve 
parental adherence to ADHD medication for their children.  These findings may support 
the belief that PCMHs improve ADHD treatment outcomes for children and thus advance 
the role of PCMHs as a viable option to improve medication adherence for this 
population.  Increased medication adherence for children with ADHD could potentially 
decrease academic and social impairment, healthcare utilization, substance use, and risky 
behaviors, all of which are detrimental to children’s long-term success.  
Limitations 
Limitations for this study were that self-report scales fundamentally have some 




recall and social desirability bias, or the desire of participants to give the “right” answer 
versus the true answer (Voils, Hoyle, Thorpe, Maciejewski, & Yancy, 2011).  Voils et al. 
(2011) further reported measures that utilize self-report could have inadequate reliability, 
with up to 20% lower rates than those obtained by other means.  However, this research 
provided an opening statement for both the MMAS–8 and BMQ–Specific scales that 
explained that there was no right or wrong answer and other people have reported the 
listed responses.  That may have quelled some of participants’ desire to provide a 
particular answer, but it would not likely have impacted memory recall.  To address this 
bias, most of survey questions asked participants to only think back as far as the last two 
weeks, which should help reduce the issue of memory recall.  Researcher bias, such as 
leading questions or wording bias, was not likely be a factor in this research because the 
survey was administered online, it was anonymous, and it utilized two validated 
instruments to obtain the research data. 
Race/ethnicity can also impact the accuracy of the results (Ramírez, Ford, & 
Stewart, 2005), as different ethnic groups may vary in their interpretation of questions, 
leading to survey misclassification (Ramírez et al., 2005).  The consent form indicated 
that participant responses were3 anonymous, which may have contributed to more 
accurate parental responses and reduced social desirability bias.  The subject variable 
(PCMH) was not randomly assigned, as each group self-selected based on their responses 
to the PCMH survey questions.  This nonrandom assignment can impact internal validity 
as a result of nonequivalent groups in the study.  Participant ethnicity was captured on the 




participant responses.  Using the validated instruments (BMQ–Specific and MMAS–8) to 
assess parental beliefs and medication adherence, as well as appropriate participant 
selection via inclusion criteria, minimized potential researcher bias.   
Some of the questions utilized in the 2007 NSCH to determine whether the child 
has a PCMH may not apply, therefore, it may be difficult to accurately determine PCMH 
status.  For example, some parents may not have had the need for a referral; therefore, 
they would respond to the question as “not applicable.”  Although the survey questions 
utilized to determine PCMH status have some gaps and may impact accurate selection of 
PCMH status by the parent, this is the current and most widely used method in other 
national studies (Boudreau, Goodman, Kurowski, Perrin, & Cooley, 2014; DuPaul, 
Carson, & Fu, 2013; Knapp et al., 2012; Knapp et al., 2013; Raphael et al., 2015; 
Strickland, Jones, Ghandour, Kogan, & Newacheck, 2011; Toomey et al., 2011) to 
determine PCMH status.  The use of the 2007 NSCH survey questions also allow for 
study comparison and mirrors the American Academy of Pediatrics determination of a 
PCMH status. 
Clustering may be a limitation if significant portions of data are derived from the 
same part of the country where large PCMH medical groups are more or less prevalent.  
Clustering refers to the idea that a large group of respondents utilize the same medical 
provider, provider group, or reside in a part of the country where there are a high number 
of PCMHs or there are very few medical homes.  This factor can impact external validity, 
leading to the inability to generalize the results to the greater population. The 




they live, thus making it easier to identify if responses are clustered in a specific state or 
region.  In addition to the above potential geographical confounder, other possible 
confounders include age, ethnicity, gender, and parent’s own previous experience with 
ADHD medication.  Each of these factors was controlled for and contained in the 
demographic questionnaire in the event the data revealed they needed to be considered in 
the analysis.  
Significance of the Study and Implications for Social Change 
This research contributes to the scholarly literature available on PCMHs and will 
fill a gap in literature by determining if PCMHs positively impact parental beliefs and 
attitudes around ADHD and medication, which is associated with increased medication 
adherence for children with ADHD.  Symptoms associated with ADHD are important 
risk markers for future life challenges (Caye et al., 2016); thus, medication adherence can 
contribute to long-term educational, psychosocial, and mental health well-being and 
maximize outcomes (Charach & Fernandez, 2013).  This research is also important for 
those who make policies regulating healthcare and agencies who influence those policies.  
Some of these agencies include: the American Academy of Pediatrics, which influences 
healthcare policy; the NCQA, which awards recognition to PCMH; the Joint 
Commission, which provides PCMH accreditation; and Centers for Medicaid and 
Medicare Services, which intends to offer PCMH designation to assist in payment 
reimbursement.  These policy-making organizations could make it a recommendation that 




policy change of this magnitude could significantly reduce the financial burden 
associated the increased academic and healthcare services required by this population. 
This study has positive social change implications as it provides valuable 
outcomes data on PCMHs, which may support the hypothesis that parental 
beliefs/attitudes about their child’s ADHD medication can be positively influenced by 
PCMHs.  This data is also important as a measure of PCMH effectiveness in improving 
outcomes and whether they are meeting the goals as mandated in the Affordable Care 
Act.  
Summary and Transition 
Chapter 1 provided an overview of ADHD, medication adherence in children with 
ADHD, the influence of parental attitudes on medication adherence, and the role of 
PCMHs and their impact on health outcomes for children with chronic conditions.  I also 
discussed the research questions, hypotheses, methodology, assumptions and limitations.  
Chapter 2 provides a detailed literature review on these topics as well as the theoretical 





Chapter 2: Literature Review 
Introduction 
This chapter presents a review of relevant scholarly literature around PCMHs, 
medication adherence, ADHD, parental beliefs/attitudes related to ADHD medication, 
and TPB.  The problem that is explored is the high rate of medication nonadherence in 
children with ADHD and the impact of PCMHs on parental beliefs about ADHD 
medication and ADHD medication adherence.  ADHD has many consequences, which 
include clinically significant academic and social impairment (Bussing et al., 2012; 
Express Scripts, 2014; Visser et al., 2014), an increased occurrence of grade retention and 
failure to graduate (Robb et al., 2011), risky sexual behaviors (Flory, Molina, Pelham, 
Gnagy, & Smith, 2006), substance use disorder (Wilens et al., 2011), poor quality of life 
(Danckaerts et al., 2010), peer rejection (Murray-Close et al., 2010), parenthood at an 
early age (Barkley et al., 2006; Reimer et al. , 2010), and increased rates of incarceration.   
Nonadherence to medication has been shown to contribute to healthcare 
utilization, (Cutler &Everett, 2010; Hamilton, Lerner, Presson & Klitzner, 2013; 
McGrady & Hommel, 2013; Toomey et al., 2011), particularly for children with ADHD. 
Unintended injuries due to risky behavior and mental health service utilization are key 
consequences that directly impact healthcare utilization.  Care provided in a PCMH has 
been associated with a reduction in healthcare utilization and improved outcomes 
(Toomey et al., 2011). Therefore, the purpose of this study was to determine if PCMHs 
have an impact on parental beliefs related to ADHD medication and ADHD medication 




Literature Search Strategy 
The literature review search strategy included a digital search of peer-reviewed 
literature through the Thoreau Multi-Database Search, Google Scholar, PsychINFO, 
PsychARTICLES, and EBSCOhost.  The literature search was focused on the last five 
years (2011–2016); however, a complete and exhaustive review was conducted, which 
also included the seminal literature.  The primary search terms included: attention-deficit 
hyperactivity disorder (ADHD), mental health, medication adherence, behavioral health, 
medication compliance, medication persistence, patient-centered medical homes, medical 
homes, the theory of planned behavior, medication adherence theories, parental beliefs 
and medication, parental attitudes toward medication, parental beliefs or attitudes about 
medication, attitudes about ADHD, beliefs about ADHD, intention to adhere, parents and 
intention to adhere to medication, role of genetics in ADHD, genetic influences in 
ADHD, cognitive behavior therapy, behavior therapy, behavior therapy effectiveness, 
psychostimulants, and ADHD medication.  Term combinations included ADHD and 
medication adherence, ADHD and genetics, ADHD and patient-centered medical hones, 
ADHD and the theory of planned behavior, medication adherence and the theory of 
planned behavior, ADHD and beliefs about medication, ADHD and medication, patient-
centered medical homes and medication adherence, and patient-centered medical homes 
and parental attitudes.  I highlighted the definition of patient-centered medical homes, 
the recent research and findings pertaining to PCMHs and medication and ADHD, the 
factors that impact medication adherence and the relationship to clinical outcomes, the 




the use of the theory of planned behavior as the theoretical framework, and the literature 
regarding the use of self-report in research. 
Theoretical Framework 
A variety of theoretical models have been utilized to understand reasons for 
medication nonadherence, including the illness career model (Parsons, 1951), the trans-
theoretical model of change (Prochaska & DiClemente, 1984), the health belief model 
(Hochbaum et al., 1952), the social exchange theory (Emerson, 1976), UTB (Jaccard, et 
al., 2002), and TPB (Ajzen, 1991).  The TPB was utilized as the framework for this 
study.  However, I have included a brief summary of the preceding theories to elucidate 
the various approaches utilized in the literature to understand medication-taking behavior.   
The Illness Career Model 
The illness career model asserts people apply a social process to help-seeking 
behavior, which can be impacted by the patient’s geography or social living environment 
(Biddle et al., 2007).  Patients will consult with those outside of the medical community, 
including family, friends, and others in their social network to assist with their medical-
related decision-making.  The advice obtained from the social circle may go against 
medical advice and be perceived as irrational by medical practitioners (Charach, Volpe, 
Boydell, & Gearing, 2008).  Moses (2011) suggested psychiatric treatment acceptability 
is influenced by peer socialization.  Those youth who have peers in their circle who also 
receive psychiatric treatment tend to be more accepting of their own psychiatric 
treatment.  Therefore, this framework has been utilized to understand how parents 




line with the theoretical approach of this study, which asserts that beliefs and attitudes of 
those in a person’s sphere of influence impact medication adherence, and would also be 
an appropriate theory for this study.  However, this research placed additional emphasis 
on the role of parental beliefs and their influence on medication adherence. 
The Trans-Theoretical Model of Change 
The trans-theoretical model of change focuses on a person’s readiness to change 
and contends behavior change occurs in the following stages: (a) pre-contemplation, 
where the person is not interested in making any behavioral changes in the near future; 
(b) contemplation, where the person considers making behavioral changes within the 
upcoming six months, but the change has not been initiated; and (c) preparation, where 
the person has implemented steps toward making the change within the next 30 days, an 
indicator that change is eminent (Prochaska & DiClemente, 1984); (d) action, where the 
person has successfully made and maintained the behavior change for under 6 months; 
and (e) maintenance, where the behavior change has been implemented for more than 6 
months (Prochaska & DiClemente, 1984).  People may often vacillate among the stages 
and not progress straight through from precontemplation to maintenance (Prochaska & 
DiClemente, 1984).  Thus, regression can occur throughout the change process.  
Medication adherence would not be considered sustained until the person reached the 
maintenance stage of this model.   
As reported in Watkins (2015), Charach et al. (2008) indicated medication 
adherence happens between the stages of action and maintenance and suggested while 




psychiatric diagnosis.  This theory was not a fit for this research because it does not 
account for the influence of the beliefs and attitudes of parents on behavior change or the 
general impact of other factors that influence a person’s decision to take action. 
The Health Belief Model 
The health belief model, which is considered one of the most frequently used 
theories related to health behavior (Orji, Vassileva, & Mandryk, 2012), has been utilized 
to explain behavior related to illness and prevention.  The focus of the model is related to 
motivation and a person’s perceptions, modifying behavior, and the likelihood that they 
will take action (Hochbaum et al., 1952).  The five factors of the health belief model that 
impact a person’s motivation and action-taking behavior are:  (a) perceived susceptibility, 
a persons’ perception of the odds of developing a condition that negatively impacts their 
health; (b) perceived severity, a persons’ belief as to the life effect the condition will 
have; (c) perceived benefit of taking action, a person’s belief that the condition is serious 
enough to warrant action, and the type of action taken is influenced by effectiveness of 
the available options; (d) barriers to taking action, in which persons may believe that they 
should take action but factors such as cost and inconvenience can adversely impact the 
follow-through with the action; and (e) cues to action, including internal and external 
triggers that prompt a person to action, which most likely occurs in the absence or 
elimination of barriers (Hochbaum et al., 1952).  This model also places emphasis on a 





Social Exchange Theory 
Social exchange theory holds that people make decisions based on their ability to 
exchange and maximize resources and rewards and minimize costs (Hamrin et al., 2010).  
In other words, individuals assess the advances they can achieve through a reciprocal 
relationship.  It is assumed that the individual or group is rational and is able to make 
rational decisions when contemplating the resource exchange.  Hamrin et al., (2010) 
assert this theory can be applicable to families as they examine the potential benefits and 
alternatives to pharmacological treatment for their child who has a behavioral health 
diagnosis.  This theory also supports the premise that previous parental experience with 
mental illness and favorable use of psychotropic medication is correlated with parents’ 
willingness to entertain psychotropic medication for their child (Hamrin et al., 2010).  
This theory of parental attitudes toward medication and mental health diagnosis could be 
applicable to this research, but this research will not evaluate the reciprocal relationship 
as a variable for adherence. 
Unified Theory of Behavior 
UTB is a commonly used theory in the literature regarding the influences of 
behavior (Jaccard, et al., 2002).  The UTB focuses on two dimensions.  The first involves 
a person’s behavior, which is influenced by the person’s knowledge and skills for 
behavioral performance, environmental restrictions, intention or decision to perform 
behavior, importance of behavior, and habit and spontaneous processes (Guilamo-Ramos, 
Jaccard, Dittus, Gonzalez, & Bouris, 2008; Olin et al., 2010).  The second dimension 




concept, expectancies, affect, and self-efficacy (Guilamo-Ramos et al., 2008; Olin et al., 
2010).  Based on this theory, it is believed that even if a person’s intentions can be 
influenced to participate in a specific behavior, behavioral action may not occur until the 
first set of factors (i.e. environmental barriers or constraints, knowledge) are addressed 
(Olin et al., 2010). This theory does address intention and attitudes as factors that 
influence behavior, and the impact of environmental barriers such as knowledge and 
parental attitudes. Thus, this theory could also be an option for this research. 
Theory of Planned Behavior 
TPB is an extension of the theory of reasoned action and was selected for this 
research (Fishbein & Ajzen, 1975).  The theory asserts the intention of a person to 
perform a specific behavior is a reflection of the motivational influences on that behavior 
(Ajzen, 1991).  According to Ajzen, the three components that influence behavior are:  
(a) attitude, (b) subjective norm, and (c) perceived behavioral control.  Ajzen further 
posits that the stronger a person’s intention to engage in a behavior, the higher the 
probability that the behavior will occur.  Subjective norms are indicative of a person’s 
beliefs related to how individuals in their social network perceive the behavior in 
question.  A person’s belief in their ability is referred to as their perceived behavioral 
control (Azjen, 1991).  Therefore, the more positive a person’s attitude and subjective 
norm, the greater the person’s perceived control as well as the likelihood of the person’s 
intention to perform the targeted behavior.   
The TPB is a popular theory utilized to investigate medication adherence for 




diseases and conditions including pain, cardiovascular disease, depression, and diabetes.  
Laba, Lehnbom, Brien, and Jan (2015) suggested intention plays an important role in 
medication adherence in chronic illnesses.  Lewis, Askie, Randleman, and Shelton-
Dunstan (2010) found friends and family influenced beliefs and the behavior, which were 
correlated with medication adherence in African American participants.  Several 
researchers found medication adherence was strongly associated with attitudes, social 
support/ social circle, and family (Ahmed & Aslani, 2013; August & Billmek, 2015; 
Charach & Fernandez, 2013, Cutler & Everett, 2010; Hébert et al., 2013; Luga & 
McGuire, 2014; Vissman, Young, Wilkin, & Rhodes, 2013).  Charach and Fernandez 
(2013) asserted parents’ beliefs and attitudes related to ADHD treatment significantly 
impact medication initiation.  However, some parents do not accept medication as an 
appropriate choice to treat their child’s ADHD-related behaviors.  Other parents evaluate 
the potential of social disapproval and possible adverse effects of ADHD medications as 
the reason for forgoing medication initiation (Bussing et al., 2012; Toomey et al., 2012).   
Social acceptability/social norms are popular themes associated with medication 
adherence and are a construct of the TPB.  Charach and Fernandez (2013), and Hébert et 
al. (2013) reported increased parental feelings and attitudes related to medication social 
acceptability coincide with their increased willingness to accept pharmacological options.  
Ludwig et al. (2011) compared individuals who live in disadvantaged and those who live 
in affluent neighborhoods. They found those who reside in low-income neighborhoods 
are more likely to experience poor social cohesion, which may perpetuate norms that 




Pillow, Naylor, and Malone (2014) utilized the TPB to evaluate the beliefs about 
stimulant medication of college students with ADHD.  The study focused on the general 
attitudes of current and past stimulant medication users and proposed that people acquire 
and alter their beliefs related to stimulants due to their connections with others.   They 
further contend that familiarity with and the experience of those who take stimulant 
medication can influence medication adherence.  Pillow et al. (2014) further reported the 
constructs of the TPB (attitudes, perceived control, social norms) may possess clinical 
and predictive value due to the significant differences found in the general attitudes 
related to stimulant use, the perception of control, and the opinions of others around the 
use of stimulants. 
Bai et al. (2015) utilized the constructs of the TPB in the design of 
psychoeducational programs for parents of children with ADHD.  Parents were divided 
into a control group or an intervention group where their ADHD knowledge, TPB 
components, and children’s ADHD symptoms were assessed.  Bai et al. found that 
interventions, which used the TPB model effectively, improved adherence behavior and 
ADHD symptoms.  Their research revealed that inaccurate disease state and treatment 
associated knowledge, poor emotional support, and feelings of isolation were the primary 
barriers to medication initiation and persistency among newly medicated patients. 
Strecher, De Vellis, Becker, and Rosenstock (1986) reported self-efficacy is 
correlated with a person’s beliefs around their capabilities to execute specific behaviors 
in certain situations.  Thus, one’s self-efficacy can vary greatly depending on the 




efficacy (Strecher et al., 1986).  This may have an impact on ADHD medication 
adherence and persistence as inappropriate effort in understanding the need for ADHD 
medication and treatment may lead to poor adherence with the prescribed medication 
regimen.  Based on the presented research and the utilization of the TPB in multiple 
health behavior studies, this theory was chosen as the best fit for this study and will 
provide context to the two research questions around parental beliefs and attitudes, and 
the influence of these beliefs on parent’s adherence to medication.  The TPB also serves 
as the basis to analyze the survey results, and represents the motivational influences that 
impact the parent’s intention to follow the prescribed medication-taking regimen by a 
healthcare practitioner.  Data related to this contention was collected via the BMQ–
Specific and MMAS–8 surveys, which may support or challenge this theory.  The results 
of this study may demonstrate that PCMHs positively impact parental beliefs/attitudes 
related to ADHD medication and improve parental adherence to ADHD medication for 
their children.  This is important because it may support the belief that PCMHs improve 
treatment outcomes and thus advance the role of PCMHs as a viable option to improve 
medication adherence for this population.  Increased medication adherence for children 
with ADHD could potentially decrease academic and social impairment, healthcare 
utilization, substance use, and risky behaviors; all of which are detrimental to children’s 
long-term success. 
Attention-Deficit Hyperactivity Disorder  
The CDC reports approximately 10% of children in the United States have been 




data suggests the overall cost of ADHD, in both children and adults, is high as $266 
billion dollars (Children and Adults with Attention Deficit/Hyperactivity Disorder, 2016) 
as ADHD can persist into adulthood.  ADHD is a neurodevelopmental disorder that 
involves the inability to control impulsive behaviors and includes difficulty with paying 
attention (CDC, 2013).  ADHD can lead to clinically significant academic and social 
impairment (Bussing, et al., 2012; Express Scripts, 2014; Visser et al., 2014), an 
increased occurrence of grade retention and failure to graduate (Robb et al., 2011), 
increased emergency room visits and unintended injuries (Merrill et al., 2009; Schwebel 
et al., 2011), increased risk of unsafe driving, suicidal behavior, eating disorders and 
parenthood at an early age (Barkley et al., 2006; Reimer et al., 2010).  Medication may 
provide children and adolescents with ADHD with a significant opportunity to achieve 
long-term treatment success if they adhere to the treatment regimen (Chacko et al., 2010).  
Visser et al. (2015) found just over 74% of children with ADHD, between the ages of 4 
and 17, had taken medication, however, ongoing adherence to medication treatment 
presents a challenge and contributes to the above detailed adverse impact of ADHD.  As 
reported earlier, up to 87% of children are non-adherent to medication (Ahmed & Aslani, 
2013). 
Etiology/Genetics 
There is a strong correlation between the involvement of multiple genes in the 
serotonin and dopamine pathways and ADHD, with approximately 76% of ADHD 
occurrences having a link to genetics (Farrone & Mick, 2010).  Neurotransmitter 




systems have been commonly hypothesized to be involved in ADHD (Banaschewski, 
Becker, Scherag, Franke, & Coghill, 2010).  This hypothesis is supported by the 
effectiveness and significant therapeutic effects of stimulant medications, the role of 
dopamine in ADHD (Del Campo, Chamberlain, Sahakian, & Robbins, 2011) and 
serotonergic genes which have been implicated in impulsivity (Banaschewski et al., 
2010).   Other researchers have postulated that the exposure to maternal cigarette smoke 
while pregnant and the exposure to lead may create a genetic predisposition to ADHD 
(Braun, Kahn, Froehlick, Auinger, & Lanphear, 2006; Froehlich, Anixt et al., 2011).  
There is also some evidence that ADHD is the result of prefrontal-striatal circuitry 
dysfunction however, limited information is available to support this theory (Dickstein, 
Bannon, Castellanos, & Milham, 2006). 
Researchers have additionally reported that there are age-related differences in the 
genetic and neurocognitive mechanism theory.  Thissen et al. (2015) argue that age is a 
contributing factor to these variations, as gene expression can change during different 
developmental stages.  Larsson, Lichtenstein, and Larsson (2006) reported ADHD-related 
hyperactivity and impulsivity decrease with age, and neurocognitive ability associated 
with genetic effects escalates with age (Polderman et al., 2007).   Thissen et al. (2015) 
also found differences in a particular dopamine receptor allele and serotonin transporter 
between adults and adolescents lending further support to this theory.  Wilcutt (2005) 
reported in the over 10,000 twin studies conducted to evaluate the etiology of ADHD, all 




symptoms.  Wilcutt further reported environmental influences accounted for the 
disparities in ADHD symptoms.   
 
Diagnosis 
Diagnosis and initial treatment for ADHD most frequently occurs when children 
are between the ages of seven and nine, or elementary school-aged, although the 
development of ADHD occurs before then (Charach et al., 2011).  ADHD is defined as:  
a continued pattern of hyperactivity-impulsivity and/or inattention that impedes a 
person’s ability to function or develop, with symptoms that present in at least two settings 
(e.g. school, home, with friends or family), and adversely impacts occupational, school, 
or social functioning.  Multiple symptoms must be evident before the age of 12 (5th ed.; 
DSM-5; American Psychiatric Association, 2013).  Additionally, parents and or teachers 
must provide information regarding the child’s symptoms to substantiate an ADHD 
diagnosis (Feldman & Reiff, 2014).  Charach et al. (2011) reported elementary school-
aged children are twice as likely to be diagnosed with ADHD as adolescents, with boys 
representing the majority of incidences.  Boys are also more likely to present with 
combined type (inattention and hyperactivity) versus inattention only symptoms 
(Feldman & Reiff, 2014).  The severity of ADHD symptoms tend to decrease as children 
age, however, most children still experience symptoms as adolescents (Charach et al., 
2011).  Symptoms can also persist into adulthood and it has been reported that up to one 
third of all children diagnosed with ADHD also have symptoms in adulthood (Barbaresi 




including psychopharmacology, behavioral interventions, and a combination of both.  
Unfortunately, researchers report the success of these interventions, even in combination; 
have been suboptimal (Murray et al., 2008).  Of important note, the diagnosis of ADHD 
is often comorbid with other mental health diagnoses, particularly conduct disorder and 
oppositional defiant disorder, with occurrence rates as high as 50% (Nijmeijer, Minderaa, 
Buitelaar, Mulligan, Hartman, & Hoekstra, 2008).  This high incidence of comorbidity 
can contribute to complexity and morbidity of ADHD. 
Adverse Impact of ADHD 
Academic achievement. Children with an ADHD diagnosis often experience 
academic difficulty and decreased academic achievement.  Robb et al. (2011) reported 
there is a significant impact on the costs associated with special education services for 
children (kindergarten to 12th grade) with ADHD compared to those without.  The 
average cost per year for a child with ADHD was $4,181 vs. $211 for a child without 
ADHD.   Grade retention also occurred significantly more often with the ADHD group 
(M = .40) vs. the non-ADHD group (M = .08), with an average cost per year of  $222 vs. 
$43 for the non-ADHD group.  Lastly, Robb et al. reported children and adolescents 
diagnosed with ADHD had a significantly greater report of behavioral misconduct 
resulting in academic suspensions, discipline, or expulsion.  The average cost for the 
ADHD group was $604 annually vs. $63 for the non-ADHD group.  The aggregate cost 
of all three (special education, behavioral misconduct, and grade retention comes to a 
total of $5,007 annually, which does not include the regular annual costs associated with 




Masseti et al. (2008) evaluated 255 children (125 diagnosed using modified 
criteria for ADHD) over a period of eight years to assess academic performance.  
Impairment was measured based on parent and teacher report as well as several of 
instruments that evaluated achievement in various academic categories. The researchers 
found children who exhibited the inattentive subtype of ADHD experienced decreased 
academic performance.   Bauermeister, Barkley, Bauermeister, Martínez, and McBurnett 
(2012) also supported the contention that inattention is associated with academic 
impairment. Lahey and Willcutt (2010) found children with ADHD exhibited poorer 
academic performance on standardized testing, and Power et al. (2012) found homework 
also to be a challenge for this population.  Marshall, Evans, Eiraldi, Becker and Power 
(2014) reported homework challenges include low energy, slow task completion, mind 
wandering, and muted alertness and should be the target of interventions.  
In a study of 178 children between the ages of 6 to 11, McConaughy et al. (2011) 
found as many as 55% of children with ADHD experienced a clinically significant deficit 
in Academic functioning, as demonstrated by lower scores on standardized and academic 
tests as well as teacher ratings of performance, when compared to children without 
ADHD.  These scores included teacher ratings of child performance at grade level, child 
effort, and academic motivation and ability. The researchers suggested that interventions 
are needed to not only address the academic impairment experienced by these children, 
but also there is a need for interventions to address the primary symptoms of ADHD, of 




Social impairment. Social impairment is a common hallmark of ADHD.  
McConaughy et al. (2011) found up to 85% of children experienced clinically significant 
social behavior impairment, which included decreased participation in social 
organizations, sports, less friends, and more difficult relationships with family and peers.  
Nijmeijer et al. (2008) reported peer rejection could occur as a result of the disruptive and 
aggressive behaviors commonly exhibited by children with ADHD.  And unfortunately, 
children who display these behaviors can be unaware of the adverse effect they have on 
others and therefore, are oblivious to their own unpopularity with peers.  But not all 
children with ADHD demonstrate aggressive behaviors.  Nijmeijer et al. (2008) reported 
some youth could become socially withdrawn, passive, shy, and display anxiety, which 
leads to poor relationship development with peers.  Bagwell, Molina and Pelham (2001) 
found children with ADHD had fewer friends and were rejected more frequently 
compared to those children without ADHD. Murray-Close et al. (2010) reported peer 
rejection is very challenging to reverse and can impede children from acquiring important 
developmental skills necessary for the successful navigation of life.  They further assert 
children might display an exaggerated self-concept that is off-putting to peers, leading to 
rejection.  Hoza et al. (2010) asserted the rejection that is experienced as a result of this 
over-confidence could lead to aggression.  Therefore, there appears to be a cycle of peer 
rejection and aggression, one contributing to the other, which ultimately impedes 
behavior change.    
The trajectory of antisocial behavior in children with ADHD has been reported to 




commences in late childhood (Polier, Vloet, & Herpertz-Dahhmann, 2012).  Moffitt, 
Caspi, Harrington, and Milne (2002) followed 1037 children from the age of three to 18, 
with a follow-up study of the cohort at age 26, and a second follow-up study by Odgers et 
al. (2007) of the same cohort at age 32.  Odgers et al. reported those children who were 
diagnosed with ADHD early in childhood (pre-school aged), and who also exhibited 
persistent antisocial behaviors throughout childhood and into adulthood, were often 
involved in violent behaviors and had more health and financial issues.  Even though this 
subset of the cohort represented only about 100 children (10%), they also accounted for 
roughly 70% of the time participants spent incarcerated.  Klein et al. (2012) also reported 
youth with ADHD (36%) had a significantly greater incarceration rate as compared to 
those without ADHD (12%), which supports the adverse impact and deleterious effects of 
ADHD. 
According to Burt, Obradovic, Long and Masten (2008), maladaptive behaviors in 
adulthood can be predicted by diminished social behavior in childhood.  Mrug, Hoza, and 
Gerdes (2001) assert hyperactive children with ADHD typically benefit from a 
combination behavior management training and medication.   Thus, treatment 
effectiveness may be decreased when medication is discontinued or children are 
nonadherent. 
Substance use disorder and other risky behaviors. Researchers reported the 
likelihood of developing substance use disorder (SUD) is increased for those diagnosed 
with ADHD. Wilens et al. (2011) reported there is a considerable increase in risk for 




occurs with ADHD, alone has been shown to be a risk factor for SUD, including tobacco 
smoking, This is important is important as Brook, Brook, Zhang, and Koppel (2010) 
reported SUD in youth with ADHD may be mediated by conduct disorder. 
ADHD in children has been implicated in the display of risky behaviors such as 
risky sexual activity and risky driving.  Flory et al. (2006) found youth with ADHD 
initiated earlier sexual activity, had an increased numbers of sexual partners, had more 
casual sex, and a greater number of pregnancies.  The researchers contend poor social 
functioning can steer youth toward affiliations with peer outcasts and outsiders who are 
more likely to participate in deviant behaviors.  Family conflict, as a result of the 
negative behaviors demonstrated by some children with ADHD may also be a 
contributor. 
Quality of life. Quality of life, which includes a person’s perception of their 
psychological, physical, and social performance, can be improved by medication.  Most 
studies that assessed quality of life and medication were those conducted with the non-
stimulant medication Atomoxetine.  In a systematic review of literature by Danckaerts et 
al. (2010), one study found medication resulting in a significant improvement in family 
engagement, behavioral health scores and psychosocial scores compared to placebo.  
Another study reported a significant increase in symptom ratings from teachers and 
parents after children took Atomoxetine.  Two studies that utilized amphetamine salts 
were reviewed and both studies revealed statistically significant increases in quality of 




how children perceive their quality of life, which is a direct impact of mental, physical 
and social well-being. 
Treatment  
Medication. Medication is the most commonly used treatment for ADHD and can 
vary based on gender and geography.  In 2012, the southern United States, specifically 
South Carolina, had the highest reported use of ADHD medication (5%), and for 
adolescent boys between the ages of 12 and 18, medication use was as over 14% (Express 
Scripts, 2014).  These rates are 72% higher than those reported for the national average, 
and there is speculation that appropriate ADHD diagnosis, school-related testing that 
penalizes teachers for poor student performance, the lack of resources in the school 
system to address behavioral issues, and lower SES, are contributors to this inflated rate 
of medication utilization (Express Scripts, 2014).  This data reflects geographic 
differences in medication use across the United States. 
The two types of medications most frequently utilized are categorized as 
psychostimulants (e.g. amphetamine derivatives, methylphenidate) and norepinephrine 
reuptake inhibitors (Charach et al., 2011).  While both have had some success in the 
treatment of ADHD symptoms, stimulants are the most frequently used medications and 
are first-line treatment for ADHD (Weyandt et al., 2014; Zuvekas & Vitiello, 2012).  
Evidence indicates non-stimulant medications are also safe and effective at relieving 
ADHD symptoms (Busche & Savill, 2014).  They are particularly effective for those who 
fail to respond to stimulants and who also have comorbid substance use disorder 




medications due to their affinity for the dopaminergic system, whereas non-stimulants 
target the norepinephrine neurotransmitter system (Weyandt et al., 2014).  However, 
researchers have also reported patients who take non-stimulants are less adherent and 
have decreased medication persistence as compared to those who take stimulant 
medications (Christensen, Sasane, Hodgkins, Harley, & Tetali, 2010).  This may be 
attributed to medication efficacy, which is one of the most commonly reported reasons 
for the discontinuance of ADHD medication. 
Feldman and Reiff (2014) reported long-acting and sustained release stimulants 
have a greater preference over short-acting stimulant medications due to once a day 
morning dosing.  This dosing schedule provides effective control of symptoms 
throughout the school day with limited side effects (Feldman & Reiff, 2014).  The long-
term use of stimulants and their cardiovascular safety profile trepidation among patients 
and practitioners.  However, Cooper et al. (2011) found there is no increased frequency 
of unexpected death in children who utilized stimulants than what is found in the general 
population.  Although these findings indicate there is no increased risk, in 2008 the 
American Heart Association recommended that practitioners conduct an 
electrocardiography prior to the initiation of treatment with stimulants (Feldman & Reiff, 
2014).   
Atomoxetine, a selective norepinephrine reuptake inhibitor, is the most well 
known non-stimulant medication (Polier et al., 2012). The investigators reported that 
although it may take a few weeks before the complete benefit of the drug is realized, the 




Newcorn, Spencer, Biederman, Milton, and Michelson (2005) reported Atomoxetine has 
also been effective in mitigating aggression related to impulsivity in those with both 
ADHD and oppositional defiant disorder.  Although some literature supports the 
effectiveness of Atomoxetine, stimulants are recommended as first line therapy, with 
short-acting stimulants demonstrating fewer side effects, which can lead to better 
adherence. 
Behavior therapy/counseling. Behavior therapy has been utilized alone and in 
combination with medication to change behavior.  Cognitive Behavior Therapy (CBT), 
which is used in both children and adults, has been recommended for children 5 and 
under, in combination with pharmacotherapy, and for children unable to tolerate 
psychostimulants (The American Academy of Pediatrics, 2011).  Antshel, Farone, and 
Gordon (2014) reported that although there is some literature that indicates CBT is an 
effective treatment option for children and adolescents, CBT has demonstrated stronger 
efficacy in adolescents (Baer & Nietzel, 1991) and in adults (Safren et al., 2010) versus 
children, and suggested CBT efficacy may be moderated by cognitive development.   
While some children may have a singular diagnosis of ADHD, it often presents with co-
occurring psychopathology, such as anxiety, mood disorders, and disruptive behavior 
(Kessler et al., 2006).  Antshel et al. (2014) found adolescents with multiple mental 
health disorders (e.g. conduct disorder, and oppositional defiant disorder) received less 
benefit from CBT than those with ADHD alone or ADHD and anxiety or depression.  




anxiety or depression did realize some gains in functioning, they remained symptomatic 
and continued to experience some functional impairment. 
Bussing et al. (2012) found negative attitudes were correlated with behavior 
therapy and counseling.  Participants reported psychotherapy and counseling were 
generally ineffective, particularly when used alone.  In addition to the cost associated 
with counseling, participants expressed concern around the stigma tied to the receipt of 
counseling and the possibility that public awareness of their counseling would have a 
devastating impact.  Behavior therapy consistency for the family and across the 
continuum of care was reported as the greatest burden of this treatment option (Bussing et 
al., 2012).  Parents can be trained on how to utilize interventions, such as positive and 
negative reinforcement, which can result in successful behavior modification and help 
their child to self-manage their behavior (American Academy of Pediatrics, AAP, 2011).   
Another behavioral intervention that has been utilized is behavior classroom 
management, which is designed to increase classroom rules compliance and productivity, 
and minimize disruptive behavior (AAP, 2011).  While behavior management is the first-
line recommendation for younger children (ages 4-5), it may not be enough to sufficiently 
reduce problematic ADHD behavior, thus the addition of medication may be required, 
per AAP treatment guidelines (AAP, 2011).  Although some children, parents, and 
teachers may find this treatment useful, it does not appear to be the most efficacious. 
ADHD Treatment Guidelines 
The American Academy of Pediatrics (2011) has provided guidelines for the 




1. Children between 4 and 5 years of age:  In areas where behavioral treatments 
are available, they are recommended first-line.  If the intervention does not 
provide a significant improvement and behavioral disturbances persist, 
methylphenidate may be prescribed, however the potential harm versus the 
benefits of starting medication at an early age should be weighed. 
2. Children between 6 and 11 years of age:  U. S. Food and Drug Administration 
approved ADHD medication and/or parent/teacher provided behavior therapy 
is recommended first line, with a preference for a combination of the two.  
The AAP reports there is strong evidence in support of the use of stimulants, 
and further recommends school involvement as part of the treatment regimen. 
3. For children between 12 and 18 years of age:  U. S. Food and Drug 
Administration approved ADHD medication is recommended with adolescent 
assent.  Medication should be used preferably in combination with prescribed 
behavior therapy. 
Medication Adherence 
Medication adherence is defined as the degree to which a person’s behavior 
matches the agreed recommendations from a health care practitioner, including following 
diet and lifestyle changes as well as taking medication (World Health Organization, 
2003).  Medication may provide children and adolescents with ADHD with a significant 
opportunity to achieve long-term treatment success if they adhere to the treatment 
regimen (Chacko et al., 2010).  Reasons attributed to medication adherence (which is 




related (e.g., efficacy; Barner, Khoza, & Oladapo, 2011), and environment-related (e.g., 
parental beliefs; Ferrin & Taylor, 2011, Garbe et al., 2012; Zetterqvist et al., 2013).  
Dawood et al. (2010) contend that for children with chronic illness, the lack of parental 
understanding of their child’s illness, reticence around therapy efficacy, and concern 
about adverse effects of medication, impact children’s adherence. Thus, parents have the 
largest impact on their child’s medication initiation and adherence (Bai, et al., 2015).    
Medication interventions have demonstrated proven success in mitigating the 
ADHD symptoms of hyperactivity, inattention, and impulsivity, which contribute to 
social and academic impairment as well as risky behaviors.  Specifically, medication has 
been shown to increase academic performance (Connor, 2005), improve mathematic 
scores (Molina et al., 2009), and enhance cognitive performance (Bedard, Jain, Johnson, 
& Tannack, 2007; Swanson, Baler, & Volkow, 2011).  In a systematic review of 
literature by Shaw et al. (2012) to compare the long-term impact of ADHD treatment vs. 
non-treatment, several studies that looked at the long-term impact of no ADHD treatment 
over a period of nine years.  Four studies indicated participants deteriorated significantly 
from baseline measures.  For example, in one study, Powers, Marks, Miller, Newcorn, 
and Halperin (2008), investigators found children who had never or who had received 
minimal pharmacologic treatment for ADHD scored significantly worse on standardized 
academic achievement tests than those who had no ADHD diagnosis.  
In another group of studies from the Shaw et al. (2012) literature review, driving, 
obesity, self-esteem, social function, academics, drugs, antisocial behavior, the use of 




ADHD.  Medication treatment achieved the greatest benefit on driving, obesity, self-
esteem, and social and academic function.  However, improvements in obesity is may be 
attributed to the side effects of amphetamines, which is appetite suppression.  Shaw et al. 
noted that although many studies reported an improvement in the outcome measures for 
those treated with medication, medication is unable to normalize or to eliminate 
completely the symptoms and adverse behaviors associated with ADHD.  Therefore, 
when individuals who have received treatment for ADHD are compared to those without 
ADHD, those without ADHD still tend to perform better. 
Attempts to increase medication adherence include enhancing parental knowledge 
and information regarding ADHD, educating parents on the safety of medication and the 
social acceptability of medication, behavior therapy, and psychoeducation (Bussing et al., 
2012).  However, Wang, Maursky-Horowitz, and Chronis-Tuscano (2015) reported 
parents own experience with ADHD could impact their child’s treatment outcome.  The 
researcher asserted this is due primarily to the manifestation of the parent’s own ADHD 
symptoms, leading to poor and/or inconsistent monitoring and adherence to their child’s 
pharmacologic treatment regimen, ultimately producing inadequate pharmacological 
response.  Wang et al. reported that interventions designed to help parents attain better 
control of their own ADHD symptoms may create a trickle-down effect that leads to 
better medication adherence for their children.  However, it is not clear as to the degree to 
which parental ADHD and the control of parental ADHD symptoms actually impact 




Demonceau et al. (2013) conducted a systematic literature review and meta-
analysis to assess interventions utilized to increase medication adherence.  Eight types of 
interventions were evaluated including (a) treatment simplification (changing dose 
schedule and/or medication formulation, (b) cognitive-educational (education in group 
settings), (c) behavioral counseling, (d) social-psycho-affective (social support and 
relationships, (e) electronically monitored adherence feedback or EM-feedback 
(electronic feedback on patient dosing history), (f) technical reminder systems (i.e. 
mobile text messages), and (g) rewards.  The researchers found patients who received 
EM-feedback had the greatest improvement (7.7%), and rewards were second.  However, 
variations in study sample size, the repetition of the intervention, method for 
randomization, and the way adherence was operationally defined in studies may have 
impacted the study results (Demonceau et al. (2013).  
Researchers revealed that while some interventions (psychoeducation and 
behavior therapy) may have some incremental impact on increased medication adherence 
in the short term (Dean et al., 2010; Hebert et al., 2013), an intervention that substantially 
increases medication adherence remains a challenge (Sitholey et al., 2011).   Methods to 
reduce the economic loss, social impairment, and poor clinical outcomes related to poor 
ADHD medication adherence remains of significant importance to healthcare 






In this research, the patient is defined as the “parent-child dyad” because for 
children between the ages of 5 and 12, the parent(s) is the one generally responsible for 
medication administration (Chacko et al., 2010).  As children age and become 
adolescents, they tend to be more vocal about their opinions related to ADHD medication 
and whether they will adhere and persist with their medication.  The patient chiefly 
determines medication adherence, although many factors can influence whether the 
patient decides to initiate, adhere, and persist with treatment.  Brown and Bussell (2011) 
argued the involvement of patients in their care is a key contributor to improved patient 
associated medication adherence.    
Age. Age has been examined extensively as a factor that contributes to 
medication adherence.  As children age, they become more vocal in their desire to be 
adherent to medication and parents wield less influence on their children’s medication-
taking behavior.  In a qualitative study by Avisar and Lavie-Ajayi (2014), six of 14 
participants completely discontinued medication after elementary school.  Selective 
adherence was reported by three of the 14 participants, and only five participants reported 
that they persisted with their medication.  However, they were also the younger 
participants in the sample.  All of the participants reported they either completely stopped 
taking their medication or only took it intermittently by the time they reached high 
school.  Of significance is that only one participant was advised by his parent to stop 




Although age has been cited as a factor that impacts medication adherence, some 
researchers dispute the role age plays in adherence.  Hebert et al. (2013) contend 
medication adherence was not significantly impacted by a child’s age.  They found there 
were two factors that positively predicted adherence:  1) child’s gender (male), and 2) the 
parent’s perception of the psychosocial benefits of medication after three months. 
The researchers further reported parent’s perceived psychosocial benefits of medication 
can be increased through their medication acceptability and through clinician-driven 
medication education, targeted toward the child, regarding the benefits of medication on 
psychosocial skills 
Socioeconomic status. Patient SES status is a significant factor that can adversely 
impact medication adherence (Brown & Bussell, 2011).  Low SES directly affects a 
patient’s access to healthcare including transportation to appointments and the pharmacy, 
as well as their ability to pay for medication and services.   Children who live in 
neighborhoods with limited access to a pediatrician and/or low-income areas may have 
worse health habits than those with higher SES (August & Billimek, 2015).  Even if the 
child has health insurance, access to preferred medication that may have fewer side 
effects or be more efficacious could be a barrier to treatment adherence.  Patients may 
also skip doses or not take the prescribed amount of medication due to the cost of 
medication costs.  Billimek and August (2014) reported that medication cost is a core 
contributor to intentional nonadherence. When the researchers assessed the role of costs 
and beliefs about medication of Mexican Americans who had type 2 diabetes, they found 




reported participants beliefs were associated with neighborhood deprivation, but income 
or the type of insurance, and the opposite was true of medication cost, where cost was 
related to type of insurance and income. 
Bussing et al. (2003) evaluated the influence of social networks and found there 
were significant differences in in network characteristics based on SES and ethnicity. 
Those networks which comprised White parents with higher SES were larger and 
included more healthcare practitioners.  Even these results suggested White parents had 
greater access to healthcare professionals and increased opportunity to seek their advice. 
African American parents leaned more heavily on an informal network, consisting of 
family and friends and reported they had adequate social support. 
Medication-Related Factors 
The most commonly reported ADHD medication-related factors attributed to non-
adherence are side effects and poor efficacy.  Medication side effects include changes in 
mood, depression, irritability, suppression of appetite, and insomnia (Singh et al., 2010; 
Toomey et al., 2012).  Toomey et al. (2012) surveyed parents of children with ADHD 
and found 21% of children no longer persisted with medication, and 42% of those 
discontinued within the first 30 days of medication initiation.  An additional 33% 
discontinued between 4 and 6 months of initiation and 4% persisted for more than 6 
months.  The researchers reported 34% was attributed to poor medication efficacy and 
62% of medication discontinuance was attributed to medication adverse effects.  




Sitholey et al. (2011) assessed 24 newly diagnosed adolescents and children with 
ADHD from India to determine the factors related to medication adherence.  The 
researchers found participant nonadherence exceeded 83% in the first month.  Medication 
side effects were reported by 65% of participants, and poor medication efficacy was 
reported by 50% of participants.  While the study results were congruent with other study 
reports on reasons for medication nonadherence, the small sample size impedes the 
generalization of the results. 
Several researchers have also cited medication side effects and poor efficacy as 
the primary reason for medication nonadherence (Cutler & Everett 2010; Laba et al., 
2015).  However, in a qualitative study to assess young people’s experiences of stimulant 
medication and ADHD, several youth reported their medication had a positive effect on 
their social behavior, increased their focus and concentration in the classroom, and 
improved their school work (Singh et al., 2010).  While several participants reported they 
experienced school work improvement, the benefits of enhanced focus and concentration 
were not completely alleviated and participants still reported they experienced significant 
difficulty with school work.  However, most of the youth expressed positive medication 
experiences and indicated they needed their medication.  They further related improved 
social behaviors of the medication with improved peer relationships. 
Environmental-Related Factors 
Parental beliefs. Parental attitudes, beliefs, and perceptions are paramount to 
medication adherence (Ferrin et al., 2012).  Toomey et al. (2012) examined why children 




ADHD and medication.  The researchers found medication discontinuation was 
correlated with positive parent agreement with the following statements: (a) “I prefer 
counseling over medicine to treat my child”; (b) “I feel that medicines to treat ADHD had 
bad side effects”; (c) “ADHD is best treated with counseling”; (d) “Sometimes [my child] 
doesn’t need to use as much ADHD medicine as the doctor prescribed”; and (e) “I worry 
about the long-term effects of ADHD medicines” (p. 766).  Therefore, parental 
perceptions and beliefs were correlated with parental behavior and medication adherence. 
Hamrin et al. (2010) suggested that parent and child ambivalence toward 
medication is created through cultural messages that facilitate fear.  Some messages, both 
cultural and not, influenced medication-taking behavior around disease and medication-
related stigma.  Hamrin et al. reported researchers found 45% of stigma was related to 
childhood mental health treatment that resulted in rejection in the school setting.  In 
response to questions around mental health issues and the treatment of children with 
medication, participants reported (a) physicians prescribed too much medication; (b) 
long-term developmental side effects are caused by medication; and (c) medication 
postponed addressing the actual child’s issues (Pescosolido, Perry, Martin, McLeod, & 
Jensen, 2007).   This research supports the contention that attitudes and beliefs impact 
parental behavior related to medication. 
Ferrin and Taylor (2011) contended illness management is directly impacted by 
the core beliefs of the patient, and suggested the treatment outcome for children and 
adolescents are most likely influenced by their attitudes.  Johnston, Seipp, Hommersen, 




environmental or psychological influences versus biological causes had a greater 
propensity to encourage medication adherence for their children.  They reported safety 
and efficacy of medication to moderate ADHD symptoms also greatly impacted parental 
medication adherence.  
In a Danish study of 62,304 children, adolescents and adults up to 49 years of age 
to determine second prescription refills of ADHD medication, only 7,441 (12.6%) refilled 
their prescription a second time (Pottegård, Bjerregaard, Kortegaard, & Zoega, 2015).  
This number represents a decrease in second prescription refills over time.  Similar 
results were found regardless of the gender, type of drug taken (methylphenidate 
immediate release, methylphenidate extended release, or atomoxetine), or age.   
However, adults discontinued medication over time at a greater rate than children and 
adolescents.  Pottegård et al. suggested this may be attributed parental involvement in 
their child’s medication taking, since parents are generally the decision-maker regarding 
medication persistence.   
Raman et al. (2015) evaluated children aged 3 to 16, who were prescribed ADHD 
medication in the primary care setting in the United Kingdom between 1994 and 2006.  
The researchers looked at both the duration of the initial treatment course and the span of 
time between the courses of treatment.  Initial treatment course duration lasted from the 
date the first medication was prescribed through the end of the last ADHD prescription 
medication treatment period. Treatment periods included a grace period of 30-days in for 
the main analysis and 60 and 90 grace periods for secondary analysis.  Children who 




persistent, and those who continued for less than 6 months were considered nonpersistent.  
The treatment gaps between treatment courses for those children who had multiple 
treatment courses were also determined.  Raman et al. found just 35% of children were 
persistent with their medication at six months following their initial prescription, even 
with a 30-day grace period.  And when given a 60-day grace period, only 57% of children 
were persistent.  Long-acting methylphenidate was also associated with medication 
persistence at the six-month mark.  The investigators supported Charach and Fernandez’ 
(2013) assertion that elements not typically measured or collected in databases, such as 
attitudes around medication may be influenced by family and/or youth attitudes. 
Nagae, Nakane, Honda, Ozawa, and Hanada (2015) assessed parental adherence 
and the factors that impact medication adherence in children who obtain outpatient 
medication.  They evaluated 30 pairs of mothers and children who ranged in age between 
7 and 17.  The investigators found when mothers acknowledged their child’s symptoms 
had improved following psychiatric visits and when mothers recognized symptom 
improvement was attributed to the effects of the medication, medication adherence was 
impacted. However, contrary to other research, no correlation was found between 
medication adherence and child age. 
Parental Experience With ADHD 
Parents who at some point were diagnosed with ADHD and prescribed 
medication for treatment are influenced by their experiences with treatment.  Parents’ 
experiences with psychotropic medication are correlated with their willingness to 




For parents who have experienced a mood disorder and who have also had good and 
successful experiences with psychiatric medication associate their positive experience 
with the acceptability of the same type of treatment for their child (Chavira, Stein, Bailey, 
& Stein, 2003).  In a study of 156 parents who had previous experiences with 
psychotropic medication, most attested to strong support for short and long-term 
treatment with medication (Post, Leverich, Fergus, Miller, & Luckenbaugh, 2002).  
Hamrin et al. (2010) asserts previous parental experience with psychotropic medication 
allows for the opportunity to more accurately establish expectations and to measure the 
cost and benefits of the medication for their children.  However, some researchers 
contend for those parents where ADHD has persisted into adulthood, the familial history 
of ADHD is correlated with lower medication adherence, which may be due to their 
inadequate management and monitoring ability related to ADHD (Gau et al.,2008).   
Medication Education/Psychoeducation 
The benefits and accuracy of information related to medication is essential to 
psychotropic medication acceptance.  Berger, Dor, Nevo and Goldzweig (2008) found 
most parents of children with ADHD had received negative information in regards to 
methylphenidate, which led to adverse attitudes about the medication.  However, over 
90% of parents and children reported the greatest influence related to their acceptance of 
methylphenidate was the medication education provided by the neurologist.  These 
findings support the theory that affirmative parental beliefs associated with prescribed 
medication can create a significant impact on medication taking behavior and adherence. 




initiation phase.  However, Johnston, Hommersen, and Seipp (2008) found it did not 
contribute to medication persistence.  Corkum et al. (1999) also supported this assertion 
and reported adherence to stimulant medication over one year did not experience the 
same impact that parental ADHD knowledge had on medication initiation.  
Bussing et al. (2012) conducted a longitudinal mixed methods study that included 
students, parents of elementary school students, and teachers.  The investigators found 
teacher-reported behavior ratings for both students with and without ADHD, indicated 
that some general negative perceptions were correlated with ADHD education.  
Participants also reported while education is an important initial step, it must be 
combined with a plan and/or strategies to be effective.  A strong and supportive social 
network that involves the family, school, and healthcare providers responsible for the 
child’s care are important for the achievement of medication adherence success (Dawood 
et al., 2010).   
Patient-Centered Medical Homes 
Definition and Recognition of PCMHs 
The concept of PCMHs originated through the Academy of Pediatrics in 1967 and 
was designed to help with the care of children with special health care needs (CSHCN; 
Sia et al., 2004).  The term medical homes are also used interchangeably with PCMHs in 
the literature.  It is estimated that children with special health care needs account for 
almost 20% of the pediatric population and encompass approximately 80% of pediatric 
health care spending (Hamilton et al., 2013).   Following the adoption of the Patient 




PCMHs, medical homes have been widely adopted across the United States (Fields, et al., 
2010).  The Patient-Centered Primary Care Collaborative (PCPCC 2013) defined 
PCMHsas a model of primary care or health delivery that takes on a team approach with 
a focus on care excellence.  According to PCPCC, primary care or pediatric providers can 
be designated as a PCMH if they meet all five components of the following criteria: 
1. Patient-Centered: Patients and families are provided with support to manage 
and to participate in their care as informed partners. 
2. Comprehensive: The health care team is fully accountable for all of the 
patient’s physical health and mental health needs. 
3. Coordinated: Health care is coordinated throughout the health system to 
facilitate transition between specialty providers, hospitals, home health, and 
community and public health. 
4. Accessible: Provides 24/7 access, via electronic or phone, offers decreased 
wait times and extended hours, and communication facilitated through health 
information technology. 
5. Committed to quality and safety: Quality improvement is demonstrated 
through information technology innovation and tools that assist families with 
informed decision-making. 
It is hypothesized that through these components that (a) patients will not 
postpone or avoid needed medical attention; (b) there is less medical and procedure 
duplication; (c) there is better chronic disease management which leads to improved 




savings such as fewer emergency room visits and accurate medication utilization 
(Patient-Centered Primary Care Collaborative, 2013). These provisions may also impact 
the effectiveness of PCMHs through the enablement of patient engagement and increased 
disease state comprehension and treatment support. 
The NCQA reports as many as 10% of primary care practices in the United States 
are recognized as a PCMH (NCQA, 2014).  The NCQA is the first organization to offer a 
program to recognize PCMHs.  However, The Joint Commission now offers a PCMH 
certification.  With increased support, more organizations continue to seek PCMH status.  
This is evidenced by (a) the Department of Defense’s intention to convert all of their 
primary care practices to NCQA recognized PCMHS (NCQA, 2014), (b) the Department 
of Health and Human Services plan to help practices become PCMHs, and (c) Medicare’s 
plan to provide reimbursement to providers who deliver chronic care through non face-to-
face means. 
Benefits of Patient-Centered Medical Homes 
Literature around PCMHs and CSHCN indicated medical homes are beneficial to 
the treatment and care of this population.  Researchers found 58% of the parents 
experienced a significant health care burden while caring for their child with special 
health care needs, but only 53% of CSHCN acquired care in a medical home (DuPaul, 
Carson, & Fu, 2013).  When patients did receive care in a medical home the receipt of 
patient-centered care, assistance coordinating care, and assistance with referrals had the 
greatest impact on the reduction of time burden for caring for CSHCN (Miller, Nugent, & 




reduction in the amount of time spent arranging or coordinating care, and a 16-19% 
reduction in the odds related to the burden of providing home care for the child.   
However, if even one of the five components of a medical home was absent, there was a 
reduction in the effectiveness of the home for families of CSHCN (Miller et al. 2013).   
This research may have a significant impact on parents seeking medical care for their 
child with ADHD and how their treatment can be more effectively managed.   
Boudreau et al. (2014) reported coordinated care is a vital medical home 
component and found children who received coordinated care, in general, had fewer 
unmet specialty health care needs.  Additionally, children who received coordinated care 
within a medical home, experienced a one third decrease in unmet specialty care needs 
(Boudreau, et al., 2014).  These results demonstrate specialty care, which encompasses 
mental health diagnosis and treatment related to ADHD, may be more sufficiently 
addressed in a medical home and lead to increased medication adherence as well as fewer 
unmet needs of parents and children with ADHD. 
In a study of over 5,000 children, Knapp et al. (2012) examined the factors related 
to having a medical home and the impact of the medical home on outcomes.  Knapp et al. 
(2012) reported those children who are socioeconomically disadvantaged and/or are 
ethnically diverse are less likely to utilize a PCMH and are more apt to have unmet 
needs.  The researchers reported this was largely due to the lack of insurance, caregiver 
strain, and paternal survey participants more likely to report they did not have a PCMH.  
Miller, Nugent, Gaboda, and Russell (2013) also supported these findings and reported 




Hamilton, Lerner, Presson, and Klitzner, (2013) suggested PCMHs create positive 
experiences for socioeconomically disadvantaged parents of ethnically diverse children 
with complex healthcare needs.  This is seen more specifically in the area of care 
coordination. The findings of Knapp et al and Miller et al. demonstrated that 
unfortunately, a significant number of children in this population are not receiving these 
important benefits.   
Family-based care and medication decision-making are key benefits of the PCMH 
(PCPCC, 2012).   This type of care may help families to provide significant influence 
over adolescent medication taking behaviors and increase their teenager’s investment in 
the treatment regimen (Hogue, Bobek, Tau, & Levin, 2014; Stille et al., 2010).  Hogue et 
al. asserted interventions that provide a focus on family, provide an avenue for parent and 
family behavior monitoring and ultimately influence medication decision-making.  A 
core feature of PCMHs is a focus on patient support and involvement in their own care.  
Patients are encouraged to actively participate in the development of their care plans and 
acknowledgement of patient culture and attitudes are woven into the treatment regimen. 
This patient-centered component is in line with the literature that has demonstrated 
increased patient adherence rates are related to patient involvement and may be a critical 
PCMH component that contributes to patient adherence to medication.  
The improvement of health outcomes is a central goal for PCMHs (Adamson, 
2011).  In a survey conducted by Raphael et al. (2015) of children enrolled in Texas 
Children’s Health Plan, which is a managed care health plan serving low-income 




department visits and hospitalizations if they had a PCMH.  PCMH communication and 
staff education were the crucial factors reported to be associated with this reduction in 
resource utilization.  A reduction in ED visits and hospitalizations reduce overall 
healthcare costs and the burden of treating chronic diseases like ADHD.  Nielsen, Buelt, 
Patel, and Nichols (2016) reported PCMHs provide (a) care plans that are personalized to 
the patient, provide medication review to help patients better understand and manage 
medication, (b) offer advice and coaching to assist patients with health goal attainment, 
and (c) help patients to connect with peers and those in the community with similar 
health experiences; who provide patient encouragement.  These benefits may improve 
medication adherence for children with ADHD and reduce healthcare spending and 
resource utilization associated with adverse ADHD behaviors (Cutler & Everett, 2010; 
Hamilton et al., 2013; McGrady & Hommel, 2013; Toomey et al., 2011),  as PCMHs 
have been shown to reduce utilization of healthcare services and are associated with 
improved health outcomes (Toomey et al. 2011). 
Medical Home Attainment 
Knapp et al. (2012) also found that White children are almost twice as likely to 
have a PCMH as ethnically diverse children, and children who had a physical or mental 
diagnosis in addition to ADHD, were up to 63% more likely not to have a medical home 
versus children with ADHD alone.  Knapp et al. (2013) agreed with these findings and 
found for children with multiple behavioral health diagnoses, the likelihood of having a 
medical home was decreased. These finding suggest PCMH attainment is significantly 




children with ADHD.  Richmond and Berry (2012) assert a person’s perceptions and 
experiences regarding health care are significantly influenced by culture.  Therefore, the 
introduction of these children to the benefits of PCMHs may decrease healthcare 
disparities and potentially reduce suboptimal healthcare experiences. 
Adams, Newacheck, Park, Brindis, and Irwin (2013) reported that over the past 12 
months, more than half of adolescents had a medical home.  Children who resided in 
homes that were non-English speaking and lower income, who were uninsured, and who 
were minorities, were also less likely to have a medical home.  Adams et al., suggested 
disparities in healthcare can be decreased for youth with lower SES and/or complex 
medical needs through the application of PCMH components, such as care coordination 
and family-centered care.   
While the majority of research indicates medical homes do improve health 
outcomes and increase the level of coordinated care for patients, there continue to be 
some impediments to the full implementation of the PCMH model.  Richmond and Berry 
(2012) reported ethnic/racial disparities related to transition services persist within 
medical homes, between White and Non-Hispanic Black children with special health care 
needs.   In their research, transition services referred to the five components that define 
the medical home.  The investigators reported roughly only 57% of CSHCN received all 
of the services that are available through the PCMH components.  This percentage is 
critical, as more than 11 million, or over 15% if children in the U.S. have special health 
care needs (U. S. Department of Health and Human Services, 2013).   This represents a 




indicate there is a lot of room to improve PCMH efficacy and compliance with program 
equality.   
The Maternal and Child Health Bureau (USDHHS; MCHB, 2013) has identified 
the outcomes that are essential to evaluating CSHCN needs, which enable the 
measurement of the national progress of the PCMH components.   As of 2013, only 43% 
of CSHCN met the standard for receipt of coordinated and comprehensive care in a 
medical home.  The measures indicated almost all CSHCN had a personal doctor or 
nurse, 75% had a place they usually go when they are sick, 65% received family-centered 
care, and 23% encountered problems in the attainment of referrals (USDHHS; MCHB, 
2013).  These less than ideal results also demonstrate a significant opportunity for 
improvement in medical home operations and service delivery. 
The greatest predictor of these reported disparities was the availability of 
adequate insurance and how services are reimbursed.  Because many of the benefits and 
services delivered in a PCMH are not always reimbursed, such as (a) referral to 
specialists, (b) assistance with medication management, and (c) time spent to develop 
patient/provider relationship (Antonelli & Antonelli, 2004; Bodenheimer, 2006; 
McAllister, Sherrieb, & Cooley, 2009), providers offset the lost revenue by limiting the 
number of non-reimbursable PCMH services they provide to CSHCN (White, 2002).  
This current reimbursement structure continues to support a fragmented system of 
healthcare delivery.  However, the Centers for Medicare and Medicaid will soon offer a 
PCMH definition and certification to allow for incentive payments, which should 




revision in Centers for Medicaid and Medicare Services policy should help to alleviate 
poor practitioner reimbursement as a barrier to the full implementation of PCMH services 
(PCPCC, 2016).   
MCHB reported insurance benefits and provider access for CSHCN was 
frequently reported as a barrier to the receipt of PCMH components, as opposed to actual 
insurance coverage.  MCHB also reported CSHCN have a greater potential to have 
insurance than the population of children in general, with as few as 3.6% of CSHCN 
reporting they did not have insurance (USDHHS, 2013), and just over 9% reporting that 
at some point within the last 12 months, they lacked insurance.  Over 33% of participants 
reported their insurance was not always sufficient to meet their child’s needs, due to 
insurance benefit design, out of pocket costs, or lack of provider access, which represents 
the larger issue for CSHCN and PCMH service attainment.  Therefore, while 90% of 
CSHCN have uninterrupted health insurance, only 60% met all of the standards for this 
core outcome.  
Patient-Centered Medical Homes Measurement 
Rosenthal, Abrams, and Bitton (2012) reported that while PCMHs have been 
recognized as a promising answer to reduce the level of fragmented care that currently 
exists in the healthcare system, population inconsistencies and variable focus on PCMHs 
based on geography make it difficult to generalize quality measures.  In an effort to 
address this issue, a core set of cost and utilization measures were developed in 2009 by 
the Patient-Centered Medical Home Evaluators’ Collaborative.  A recommended core 




children who have been prescribed ADHD medication.  This measure is designed to 
quantify the effectiveness of behavioral health care and to evaluate the percentage of 
children who have been newly prescribed ADHD medication and have had at least three 
follow-up visits within 10 months (Rosenthal, Abrams, & Bitton, 2012).  One of the three 
visits must have occurred within the 30 days of when the initial ADHD medication was 
dispensed (Rosenthal et al., 2012).  Grabowski (2012) also supports the use of medication 
adherence as an effective performance measure of PCMHs, as medication adherence is a 
significant determinant of treatment outcomes (Dean et al., 2010). 
Additional issues with the accurate measurement of PCMHs include the variation 
in the individual components of PCMHs and the way the components may work in 
combination to impact PCMH effectiveness (Alexander & Bae, 2012).  It is important to 
keep in mind that research that finds PCMHs lack effectiveness in their ability to improve 
outcomes may have more to do with poor execution of PCMH components and less to do 
with the PCMH model itself (Alexander & Bae, 2012).   For example, some PCMHs may 
spend more time developing the patient/provider relationship, which can have an effect 
on patient trust in the provider, and positively influence patient adherence.  However, this 
research will not examine component execution, but it may be an area for future research.  
PCMH success and improved health outcomes are already being realized in the 
state of Missouri.  Care Management Technologies (2016) reported Missouri is the first 
to take advantage of the federal incentives earmarked for states to implement medical 
homes.  Their data analytics tool, which is in line with the information technology core 




agency, MO HealthNet, to track claims data, manage individualized care goals, identify 
at-risk patients, implement targeted care management interventions, and monitor patient 
progress with those goals.  During the first year of implementation, the state saved $31 
million dollars, which were largely attributed to hospitalizations, unnecessary emergency 
room visits, and care for enrollees with chronic mental and physical health disorders. 
(Care Management Technologies, 2016). The tremendous success of the medical home 
program in Missouri demonstrates the significant impact program implementation can 
have not only on state finances, but also more importantly on patient health outcomes.  
Summary and Conclusions 
The review of the literature revealed ADHD is a chronic mental disorder that 
affects a significant number of children in the United States with treatment costs in the 
billions (Cutler & Everett, 2010).  The exact reason for ADHD development is unclear, 
however, there is convincing evidence that genetics play a central role in ADHD etiology 
(Banaschewski et al., 2010).  Non-adherence to ADHD medication is reported to be as 
high as 87% (Ahmed & Aslani, 2013), and researchers reported some of the greatest 
contributors to non-adherence include parental beliefs, medication side effects, 
medication efficacy (Toomey et al. 2012), patient age (Avisar & Lavie-Ajayi, 2014), and 
SES (Brown & Bussell, 2011).  Uncontrolled symptoms of ADHD (inattention, 
hyperactivity, anxiety, and aggression) can lead to social and academic impairment, risky 
behavior, and diminished quality of life (Danckaerts et al., 2010; McConaughy et al., 
2011; and Robb et al., 2011).  McClain and Burks (2015) reported treatment received in a 




suggested that the increased engagement in treatment could impact their opinions 
regarding the value of treatment and increase ADHD symptom management.  Litzenburg 
(2014) also suggested that an increase in shared decision-making between medical 
personnel and caregivers could result in improved ADHD medication adherence.  This 
literature supports the use of PCMHs, which utilize a shared approach and increase 
patient treatment engagement. 
PCMHs have demonstrated that they not only positively impact treatment and 
health outcomes, but they also provide significant savings related to hospitalizations and 
the management of chronic mental and physical illnesses (Care Management 
Technologies, 2016).  However, the lack of consistency in PCMH definition and PCMH 
component implementation/emphasis, create difficulties in the accurate measurement of 
PCMH effectiveness and differentiation between PCMH effectiveness and poor PCMH 
execution.  The majority of researchers indicated that PCMHs do improve patient 
outcomes, particularly for CSHCN, although some PCMH components can have a greater 
impact on certain patient outcome measures, even though all components are important.   
The purpose of this quantitative research was to examine the impact of PCMHs 
on parental beliefs (benefits vs. risks) about ADHD medication and ADHD medication 
adherence.  This study will address the gap in research related to the efficacy of PCMHs 
and their influence on parental ADHD beliefs, as parental beliefs are a strong predictor of 
medication adherence (Ferrin & Taylor, 2011).  The results of the study will determine 
the role of PCMH impact on parental beliefs/attitudes around ADHD medication and 




what is known about PCMH’s and their ability to improve treatment outcomes, and thus 
advance the role of PCMHs as a viable option to improve medication adherence for this 
population.  Increased medication adherence for children with ADHD may decrease 
academic and social impairment, healthcare utilization, substance use, and risky 
behaviors; all of which are detrimental to children’s long-term success. Chapter 3 will 
include the study design and rationale, methodology (including population, sampling, 





Chapter 3: Research Method 
Introduction 
The purpose of this study was to determine if PCMHs have an impact on parental 
beliefs related to ADHD medication (benefits vs. risks) and on parental ADHD 
medication adherence.  In this chapter I detail the research design, population, sample, 
instrumentation, data collection, and the plan for statistical analysis. 
Research Design and Rationale 
The nature of this study was quantitative and utilized a self-report survey 
distributed via Qualtrics to determine if PCHMs influenced parental beliefs and 
adherence to ADHD medication.  There was one subject variable, PCMH, and two 
dependent variables, parental beliefs about ADHD medication (benefits vs. risks) and 
parental ADHD medication adherence. A multivariate analysis of covariance 
(MANCOVA) was used to analyze the data.  Potential covariates including age, ethnicity, 
gender, education, SES, geography, and parent’s own experience with ADHD medication 
were included in the demographic questionnaire.  A quantitative survey was the most 
effective method to obtain this data because it allowed me to capture data from a large 
representative sample of parents who have children with ADHD and also allowed the 
participants to remain anonymous.  This design choice also allowed me to statistically 
test differences between groups and advance what is known about the impact of PCMHs 







The target population was parents with children between the ages of 5 and 12 who 
had been diagnosed with ADHD and who had been prescribed ADHD medication for at 
least three months.   
Sampling 
A nonprobability self-selected sample of convenience was recruited through 
Qualtrics and was drawn from parents who resided within the United States.  The 
inclusion criteria for survey participation included: 
1. Parents must have a child diagnosed with ADHD between the ages of 5 and 
12. 
2. The child must have been prescribed medication for at least three months. 
All who met this inclusion criterion were eligible to participate in the study. This 
sampling strategy was chosen because of the large number of participants needed for the 
survey and the limited access to this population via other means.  A power analysis using 
G*Power 3.1 was conducted (Faul, Erdfelder, Buchner, & Lang, 2009) with a suggested 
total sample size of 292.   
Recruitment, Participation, and Data Collection 
Following approval from the Walden Institutional Review Board (IRB), the 
survey was made available to potential respondents in the United States with set criteria 
through the Qualtrics website (https://www.qualtrics.com).  All participants were 




Next button.  Qualtrics is only a medium for data collection, and they do not keep or 
utilize information collected from surveys.  Survey data was collected from 299 
participants within 48 hours of the launch of the survey. 
There were four parts to the survey.  The first part of the survey gathered the 
following demographic information:  age, ethnicity, gender, SES, education, geographic 
location, and parent’s own experience with taking ADHD medication (Appendix A).  
Participants then proceeded to the first set of survey questions (see Table 1), which were 
taken from the 2007 NSCH (Centers for Disease Control and Prevention/National Center 
for Health Statistics, 2007).  These questions were designed to determine whether or not a 
person had a PCMH, also referred to as PCMH status, and they have been used by other 
investigators to determine PCMH status (Boudreau et al., 2014; Knapp et al., 2013; 
Toomey et al., 2011).  Participant responses determined the group in which the parents 
were placed: PCMH or non-PCMH.  The next 10 questions came from the BMQ–
Specific scale and assessed parental beliefs about ADHD medication (benefits vs. risks), 
followed by the 8-question MMAS–8, which assessed ADHD medication adherence 
(Morisky et al., 2008).  Once participants answered all of the questions or if they felt they 
did not want to complete the survey, they could exit out of the survey by closing the 
page.  Participants’ data was anonymous and they were not contacted for any reason 
following survey completion. 
Instrumentation 
Each of the survey instrument authors had been contacted and permission to 




in the public domain and therefore the PCMH status questions did not require permission 
for use; however, I contacted the U.S. Department of Health and Human Services to 
advise of this proposed research. 
National Survey of Children’s Health (2007) 
The questions in Table 1 were used to determine PCMH status (subject variable):  
PCMH or  non-PCMH.  Survey data from the 2007 NSCH was used to determine 
whether the parent utilized a PCMH or a non-PCMH for their child’s healthcare (Toomey 
et al., 2007).  The NSCH is an accepted method for determining PCMH status and has 
been used in several peer-reviewed studies. To meet the criteria for having a PCMH, 
participants must answer one of the following to the 12 survey questions (see Table 2): 
Yes, Always, Usually, Not a problem, Very Satisfied. 
Beliefs About Medicines Questionnaire 
This study utilized the BMQ to assess core beliefs that influence parental 
adherence to ADHD medication (Horne et al., 1999).  The questionnaire is divided into 
two sections:  the BMQ–Specific and the BMQ–General. The BMQ–Specific evaluates 
beliefs related to prescribed medication for a specific disease or illness and is made up of 










Questions to Determine PCMH Status From the 2007 NSCH 
A personal doctor or nurse 
1.  Do you have one or more persons you think of as your child’s personal doctor or 
nurse? 
Family-centered care 
1.  During the past 12 months, how often did child’s doctors and other health care 
providers spend enough time with (him/her)? 
2. During the past 12 months, how often did child’s doctors and other health care 
providers listen carefully to you? 
3. When child is seen by doctors or other health care providers, how often are they 
sensitive to your family’s values and customs? 
4.  In the past 12 months, how often did child’s doctors or other health care providers 
help you feel like a partner in  (his/her) care? 
5.  When you (or your child) needed an interpreter, how often were you able to get 
someone other than a family member to help you speak with (his/her) doctors or other 
health care providers? 
Problem free referrals* 
1. Was getting referrals a big problem, a small problem, or not a problem? 
A usual source of care 
1.  Is there a place that your child USUALLY goes when (he/she) is sick or need advice 
about (his/her) health? 
2.  Is there a place that your child USUALLY goes when (he/she) need routine preventive 
care, such as a physical examination or well-child check-up? 
Coordinated care 
1.  During the past 12 months, how often did you get as much help as you wanted with 
arranging or coordinating your child’s care? 
2.  Overall, are you very satisfied, somewhat satisfied, somewhat dissatisfied, or very 
dissatisfied with the communication among child’s doctors and other health care 
providers? 
3.  Overall, are you very satisfied, somewhat satisfied, somewhat dissatisfied, or very 
dissatisfied with communication among providers and school, special education program 










Personal Provider Yes 
Comprehensive Care  
• Usual Source of care  Yes 
• Getting a referral is not a problem  Not a Problem 
Family-Centered Care  
• Spent enough time Usually or Always 
• Listened carefully Usually or Always 
• Was sensitive to family values and customs Usually or Always 
• Provided needed information Usually or Always 
• Partnered in care Usually or Always 
• Able to get someone other than family member to help 
interpret (if applicable) 
Usually or Always 
Care Coordination  
• Get help coordinating care Usually or Always 
• Satisfied with communication between providers Very Satisfied  
• Satisfied with communication between providers, 
school, and other programs 





The first 5 questions are related to the necessity of ADHD medication to improve health 
(benefits), and the second 5 questions are related to the concerns about possible ADHD 
medication side effects (risks). The BMQ–Specific was used in this research. 
The BMQ–General focuses on a person’s general beliefs about prescribed 
medication for treatment.  Because this study is interested in understanding specific 
parental beliefs about ADHD medication and the benefits and risks of taking it, only the 
BMQ–Specific was used in this research.  Additionally, the General Harm scale did not 
reach statistical significance when correlations between the scale and medication 
adherence were evaluated.  Horne et al. (1999) also recommended the General Harm 
scale be used with caution following results that indicated poor internal consistency in the 
asthma, cardiac, and general medical groups.  
Participants responded to the BMQ–Specific survey questions via their agreement 
with each question, which can range from 1 = strongly disagree to 5 = strongly agree.  
Scores from both the necessity and concerns group of questions were summed, with 
scores for each scale having a possible range between 5 and 25. Higher positive 
difference scores indicate that the participants perceive the medication benefits are 
greater than their risks and vice versa for a negative score.  This calculation of benefits 
versus risks is known as the Necessity-Concerns differential (Horne et al., 1999). 
Reliability and Validity of the Beliefs About Medicines Questionnaire 
The BMQ scale development included six different illness groups:  (a) asthma (n 
= 78), (b) diabetes (n = 99), (c) renal dialysis (n = 47), (d) cardiac (n = 120), (e) 




representative of frequently espoused beliefs about medication were taken from 16 
studies and the investigator-initiated interviews of 34 chronically ill patients.  Several 
researchers have utilized the BMQ as an effective method for measuring beliefs about 
medication.  Conn et al. (2005) used the BMQ to assess beliefs about medication and 
medication adherence in children with asthma.  Brown et al. (2005) also used the BMQ to 
evaluate beliefs about antidepressants.  Horne et al. (1999) reported the BMQ is suitable 
to assess beliefs in all disease states and medication types.  
The four measures that were utilized in the development of the BMQ were the 
Illness Perception Questionnaire (IPQ; Weinman, Petrie, Moss-Morris, & Horne, 1996), 
the Reported Adherence to Medication Scale (Horne et al. 1999), the Sensitive SOMA 
Scale (Horne, Faasse, Cooper, Diefenbach, Leventhal, Leventhal, & Petrie, 2013) and 
single measures assessing medication-related cognitions.  Horne et al. (1999) reported the 
psychometric properties of the IPQ were assessed in seven chronically ill groups of 
patients, and found the discriminant and predictive reliability, test-retest reliability, and 
concurrent reliability were all within acceptable limits.   
The Reported Adherence to Medication Scale was developed by Horne et al. 
(1999) for the BMQ study to assess medication adherence.  It contained four questions: 
two scored on a likert scale and two as direct questions.  Responses were summed for 
each question to provide a total medication adherence score, with better medication 
adherence indicated by higher scores.  Scores ranged from 0.6 to 0.83 for Cronbach alpha 




The Sensitive SOMA Scale assessed participant’s personal sensitivity perceptions 
to the possible side effects of medicine.  At the time of the BMQ development, this scale 
was still under development; however, internal reliability using Cronbach’s alpha in both 
groups was reported to be acceptable (general medical = 0.80 and cardiac = 0.78).  Single 
measures assessing medication-related cognitions were used to evaluate the psychometric 
properties of the BMQ. 
Criterion validity for the BMQ–Specific-Necessity scale was determined via 
correlation with the IPQ scales:  Timeline and Identity and correlation with medication-
related cognition statements.   BMQ–Specific-Necessity scores were positively correlated 
with the IPQ Timeline scores (Spearman r = 0.49, p < 0.001), which evaluated the likely 
length of the illness, and the IPQ Identity scores (Spearman r = 0.24, p < 0.05), which 
evaluated the perceived severity of symptoms.  A negative relationship between the 
medication-related cognition statement, “I can cope without my medicines” (Spearman r 
= -0.44, p < 0.001; Horne et al., 1999, p. 18), which assessed medication related 
cognitions, and the BMQ-Specific-Necessity scale also supported the criterion validity of 
the instrument. 
Criterion validity for the BMQ–Specific-Concerns scale was determined in 
several ways: (a) the positive correlation between BMQ–Specific-Concerns scale scores 
and the following medication-related cognition statements of the asthmatic group, “I 
cannot always trust my medicines” (Spearman r = 0.33, p < 0.005; Horne et al., 1999, p. 
18) and “I would like to change my present treatment” (Spearman r = 0.37, p < 0.001; 




Concerns scale and the medication-related cognition statement, “I have been given 
enough information about my medicines” (Spearman r = -0.45, p < 0.001; Horne et al., 
1999, p. 18)  (), which indicated that the person would like more information about their 
medication; and (c) the positive relationship between the BMQ–Specific-Concerns scale 
and the general medical and cardiac groups scores on the Sensitive Soma Scale 
(Spearman r = 0.5, p < 0.001), which indicated a person’s individual sensitivity to the 
side effects of the medicines. 
The post-hoc Tukey’s HSD tests compared the BMQ mean scores across the 
illness groups to determine if the scale could distinguish between patient illness groups.  
Discriminant validity of the Specific-Necessity scale was confirmed and indicated the 
diabetic group had significantly greater scores than all other groups (M = 21.26, p < 
0.01), and the patients in the asthmatic group (M = 19.67, p < 0.01) attained significantly 
greater scores than the psychiatric group (M = 17.72, p < 0.01).  Significantly greater 
Specific-Concerns were also seen in the asthma (M = 15.76, p < 0.01) and psychiatric (M 
= 15.60, p < 0.01) groups compared to the others. 
Morisky Medication Adherence Scale–8 
Lastly, the MMAS–8was used to assess the parent’s adherence to ADHD 
medication, which is a validated instrument that has been reported to be reliable for any 
medication and/or disease state (Horne et al., 1999).  Participants answered eight 
questions from the MMAS–8 regarding adherence to ADHD medication (dependent 
variable) for their children (Krousel-Wood, Islam, Webber, Morisky, & Munter, 2009; 




Morisky Medication Adherence Scale–8 Reliability and Validity 
Internal consistency, as measured by Cronbach’s alpha, was 0.83, and was 
significantly correlated with the validated MMAS–4 (r = 0.64, p < .05).  Morisky et al. 
(2008) reported predictive validity of the MMAS–8 was evaluated via correlations with 
patient control of their blood pressure, stress, social support, knowledge, and satisfaction 
with their visits to the clinic.  Morisky et al. reported those with high scores of 8 were 
more apt to have controlled blood pressure versus those who had medium or low scores.  
Thus, a significant correlation between the MMAS–8 and blood pressure was found (χ2 = 
6.6, p < .05).  They also found that patient knowledge, stress level, coping, satisfaction, 
knowledge, and medication complexity were significant related to medication adherence. 
High medication adherence was significantly more likely to occur when patients 
expressed greater medical regimen knowledge, satisfaction with their medical care, 
experienced positive social support from family members, and had more robust coping 
behavior.  It is important to note that validation of instruments that capture parent’s 
reported medication adherence for his/her child is difficult, largely due to social 
desirability and parent concern for potential legal consequences. 
Morisky Medication Adherence Scale–8 Scoring 
Eight questions are included in the MMAS–8.  Questions 1-7 are scored as yes or 
no.  Question 8 uses a likert scale ranging from “Never” to “All of the time”.  A total 
score of 8 indicates high parental adherence to ADHD medication, a total score of 6 or 7, 
indicates medium adherence to ADHD medication, and a total score of 5 or less indicates 




Data Analysis Plan 
This quantitative study evaluated the impact of PCMHs on parental beliefs about 
ADHD medication and their ADHD medication adherence.  The data was analyzed using 
the SPSS 24.0 software package.  MANCOVA was utilized to determine if there were 
differences in parental beliefs about ADHD medication (benefits vs. risks) and ADHD 
medication adherence (dependent variables) between the PCMH (subject variable) and 
non-PCMH groups. Data was reviewed for missing values and outliers.  If outliers are 
detected, they were removed prior to running the MANCOVA.  However, the survey was 
be set up to require each question to be answered in order to proceed to the next question.  
This reduced the potential of skipping any questions.  Only completed surveys submitted 
through Qualtrics were included in the analysis.  The following statistical assumptions 
were analyzed and reported for MANCOVA:  Multivariate normality, linearity, 
homogeneity of variances.  The type of test was an F test (One-way MANOVA) and a 
between groups subject variable. There was one subject variable, PCMHs, with two 
levels, yes or no.  There were two dependent variables: 1) parent’s beliefs about ADHD 
medications, and 2) adherence to ADHD medication.  The results were interpreted using 
an effect size of .15, alpha of .05, and power set at .95. 
Research Questions 
RQ1: Is there a difference between parental beliefs about ADHD medications 





H01: There is no significant difference in parental beliefs about ADHD 
medication (benefits vs. risks) between PCMH and non-PCMH groups. 
Ha1: There is a significant difference in parental beliefs about ADHD 
medication (benefits vs. risks) between PCMH and non-PCMH groups. 
RQ2: Is there a difference between parental adherence to ADHD medication, as 
measured by the MMAS–8 between PCMH and non-PCMH groups? 
H02: There is no significant difference in parental adherence to ADHD 
medication between PCMH and non-PCMH groups. 
Ha2: There is a significant difference in parental adherence to ADHD 
medication between PCMH and non-PCMH groups. 
Threats to Validity 
The survey was distributed through Qualtrics, and thus, there is no way to ensure 
equal participant representation (e.g. ethnicity, age) from across the country.  There was 
also the possibility that the two groups (PCMH and non-PCMH) were not be equally 
represented, or have the same number of participants in each group.  Both of these 
situations pose a threat to external validity, thus limiting generalization of the results.   
Self-report also inherently has some weaknesses.  Voils, Hoyle, Thorpe, 
Maciejewski, and Yancy (2011) posited instruments that utilize self-report could 
demonstrate inadequate reliability.  They report these measures are typically 10-20% 
below the rates acquired through other methods.   Memory recall and the tendency to 




Social desirability response bias can also be an issue with self-report and 
instrument validity.  Van de Mortel (2008) reported some researchers have utilized a 
social desirability scale to determine and/or to control for this bias in their research.  The 
researchers reported that for those who did choose to use a scale, almost 50% of them 
reported social desirability did impact study responses.  Therefore, these threats were 
considered in the data analysis process. 
To minimize self-report bias, a statement was written at the beginning of the 
MMAS–8 and the BMQ–Specific that encourages participants to be as honest as possible 
and references that others have made similar statements.  Therefore, participants may 
have been more likely to report a true answer.  Equal participant representation cannot be 
controlled, as participants were a convenience sample distributed via Qualtrics, however 
the data was collected anonymously and therefore minimized self-report bias.  Threats to 
construct validity were minimized through the use of validated instruments (BMQ–
Specific and MMAS–8), which provided appropriate and consistent variable 
operationalization, question wording and strong instrument design.  Statistical conclusion 
validity was minimized through the analysis and report of the following statistical 
assumptions for MANOVA:  multivariate normality, linearity, and homogeneity of 
variances.  High statistical power, which was set at .95 also reduced the likelihood of 
committing a type I or type II conclusion error.    
Ethical Procedures 
Following approval of the Walden Institutional Review Board, the survey was 




consent form by ticking the “Next” box, and were advised that survey participation was 
completely voluntary and anonymous.  Participants could withdraw from participation in 
the study at anytime without penalty.  The electronic survey data was stored securely on a 
password protected an encrypted computer and kept for five years.  No participant names 
or contact information was be collected, only a participant identifier for data management 
purposes.  Only this researcher and statistician had access to survey data.  Participants 
were only excluded for the following reasons:  a) if the parent does not have a child 
within the specified age range, b) the participant’s child has not been diagnosed with 
ADHD, or c) the participant’s child has not been prescribed ADHD medication within the 
last 3 months.  Incomplete surveys were not be included in data analysis, as all questions 
had to be answered in order for participants to reach the end of the survey. 
Summary 
Chapter 3 reviewed the research methods, including the utilization of a 
quantitative survey design and the use of Qualtrics to distribute the survey.  The sampling 
strategy included 294 parents of children with ADHD between the ages of 5 and 12, who 
have been prescribed medication for at least three months.  The survey included a 
questionnaire to determine PCMH status, the MMAS–8 questionnaire to assess parental 
ADHD medication adherence, and the BMQ-8 to assess parental ADHD medication 
beliefs.  Completion of a participant consent form was required to participate in the study.  
The data analysis plan utilized a MANCOVA to compare the differences between the 










Chapter 4: Results 
The purpose of this study was to determine if PCMHs have an impact on parental 
beliefs about ADHD medication (benefits vs. risks) and parental ADHD medication 
adherence.  Survey data were gathered from 294 parents of children diagnosed with 
ADHD.  Demographic data and data from the BMQ–Specific, and the MMAS–8 were 
collected from parents of children with ADHD.  PCMH questions from the 2007 NSCH 
were utilized to determine group assignment.  In this chapter I review the data collection, 
analytic procedures, and statistical results.  The following research questions and 
hypotheses were examined:  
RQ1: Is there a difference in parental beliefs about ADHD medications (benefits 
vs. risks), as measured by the BMQ - Specific scale between PCMHs and non- 
PCMH groups?  
H01:  There is no significant difference in parental beliefs about ADHD 
medication (benefits vs. risks) between PCMH and non-PCMH groups. 
Ha1: There is a significant difference in parental beliefs about ADHD 
medication (benefits vs. risks) between PCMH and non-PCMH groups. 
RQ2: Is there a difference in parental adherence to ADHD medication, as 
measured by the MMAS–8, between PCMHs and non- PCMH groups? 
H02: There is no significant difference in parental adherence to ADHD 
medication between PCMH and non-PCMH groups. 
Ha2: There is a significant difference in parental adherence to ADHD 





The original survey host, SurveyMonkey, confirmed on August 4, 2016 that they 
would be able to recruit and distribute the survey to the targeted population for this 
research via their proprietary database to target participants.  However, on April 24, 
2017, the week prior to the survey launch, SurveyMonkey advised that they no longer 
had access to my targeted population and could not distribute my survey.  Thus, the new 
survey vendor, Qualtrics, was selected and hosted the survey through an anonymous 
survey link on the Qualtrics website (https://www.qualtrics.com).  Parents were invited to 
participate in the survey via Qualtrics on May 10, 2017.  I received 299 responses by 
May 11, 2017, following participant consent.  The approved Walden University IRB 
study number was 05-05-17-0475291.  
Description of the Sample 
Table 3 displays the frequency counts for the demographic variables in the study.  
Most of the parents were White (73.8%) and female (71.1%).  Morgan, Staff, Hillemeier, 
Farkas, and Maczuga (2013) reported minority children between kindergarten and eighth 
grade were 69% less likely to have an ADHD diagnosis than White children.  Walsh et al. 
(2013) and You, Nam, and Son (2015) also reported up to 88.8% of the time, mothers 
were responsible for giving medication at home.  These studies support the demographic 
breakdown of this study, which is proportional for the population of interest.  Incomes 
ranged from under $25,000 to over $100,000 with a median of $62,500.  Most had 
attended some college (34.4%) or had earned a bachelor’s degree or higher (41.2%).  




was nationally diverse with at least one survey from 43 different states.  The most well 
represented states were California (11.9%), Florida (9.5%), New York (7.5%) and Texas 
(6.8%).  The PCMH criteria met ranged from 1 – 12 (M = 8.26, SD = 2.89).  Twenty-
seven parents, which represented approximately 10% of the sample, met the PCMH 







Demographic Frequency Counts 
________________________________________________________________________ 
 




White or Caucasian 217 73.8 
Black or African American 36 12.2 
Native American or Alaska Native 6 2.0 
Asian 4 1.4 
Hispanic or Latin American 27 9.2 
Other race not described here 4 1.4 
Gender 
Male 85 28.9 
Female 209 71.1 
Income  
$0 - $25,000 49 16.7 
$25,001 - $50,000 97 33.0 
$50,001 - $75,000 71 24.1 
$75,001 - $100,000 45 15.3 
More than $100,000 32 10.9 
Education 
Did not complete high school 6 2.0 
GED or high school diploma 66 22.4 
Some college 101 34.4 
Bachelors degree or higher 121 41.2 
Personally taken 
medication for ADHD 
Yes 87 29.6 
No 207 70.4 
State 
California 35 11.9 
Florida 28 9.5 
New York 22 7.5 
Texas 20 6.8 
All others combined 189 64.3 




Based on the MMAS–8 guidelines (Morisky et al., 2008), most parents scored at a 
low level of adherence to ADHD medication (43.2%), 28.6% scored at a medium level of 
adherence, and 28.2% scored at a high level of adherence.  Children were diagnosed with 
ADHD at a mean age of 6.27 years (SD = 1.91), and at the time of the survey had an 
average age of 9.04 years (SD = 2.04).  They received their first ADHD prescription at an 
average age of 6.64 years (SD = 1.92; Table 4).  
Table 4 
 
Descriptive Statistics for Selected Child Demographics 
________________________________________________________________________ 
                                                           
Score                                                                 M             SD          Low            High         
________________________________________________________________________ 
 
Age child diagnosed with ADHD 6.27 1.91 3.00 12.00 
Age of child 9.04 2.04 5.00 12.00 
Age of first ADHD prescription 6.64 1.92 3.00 12.00 
________________________________________________________________________ 
Note. N = 294 
 
Table 5 provides the psychometric characteristics for the summated scale scores 
from the PCMH, benefits, risks, differential, and adherence scales.  The Cronbach alpha 
coefficients ranged from α = .79 to α = .80.  This suggested that all scales had adequate 






Psychometric Characteristics for Summated Scale Scores 
Scale M SD Low High Cronbach’s alpha 
Benefits 17.68 3.82 8.00 25.00 .80 
Risks 16.84 4.06 7.00 25.00 .79 
Differentiala 0.84 4.94 -14.00 15.00 n/a 
Adherence 5.86 2.15 0.50 8.00 .80 
Note. N = 294. a Differential = Benefits scale – Risks Scale 
Statistical Assumptions 
Initially, 299 people completed the survey. Boxplots identified five univariate 
outliers in the benefits scale, and these were removed from the sample (Appendix D).  No 
outliers were detected in the risks scale.  Once the outliers were removed, the differential 
score was calculated.  This left a final sample of 294, which exceeded the recommended 
sample of 292 participants.  The following statistical assumptions were analyzed and 
reported for MANCOVA: multivariate normality, linearity, and homogeneity of 
variances.  Skewness and kurtosis were also evaluated (Table 6), and the assumption of 
multivariate normality was met.  The assumption of linearity was examined using 
scatterplots, and this assumption was met (Appendix E).  For the MANCOVA model, 
Levene’s test for homogeneity of variances found all scales to have equal variances 
across groups (benefits [p = .861], risks [p = .301], differential [p = .031], adherence [p = 
.971]), and thus, this assumption was also met.  
Hypothesis Testing 
A MANCOVA was conducted to determine if there were significant differences 




ADHD medication (dependent variables: benefits, risks, differential) and adherence to 
ADHD medication (dependent variable).  An adjustment was made for the following four 
covariates:  parent’s race, parent’s gender, parent’s income, and parent personally having 
taken ADHD medication (Table 6).  Following the adjustment, the multivariate analysis 
of Pillai’s trace = .032 was significant, F (3, 280) = 3.05, p = .029, partial η2 = .032. 
A step down analysis was completed and a significant difference was found 
between the PCMH and non-PCMH groups on the differential scale (F [1, 282] = 7.68, p 
= .006, η2= .03) when controlling for parental race, gender, income, and personally 
having taken ADHD medication.  The differential scale is a measure of parental beliefs 
about the benefits versus risks of ADHD medication.  The mean differential score for the 
PCMH group was M = 3.59 and M = 0.56 for the non-PCMH.  Both differential scores 
were positive, but it was significantly higher for the PCMH group.  This indicated there 
was a significant difference between groups and demonstrated that PCMH parents scored 
higher in their beliefs that the benefits outweighed the risks of ADHD medication.  
Therefore, the null hypothesis for the first research question was rejected.   
However, there was no statistically significant difference between the PCMH and 
non-PCMH groups for the risks scale (F [1, 282] = 2.74, p = .10, η2 = .01) or the benefits 
scale (F [1, 282] = 3.55, p = .06, η2 = .01) when controlling for the covariates.  The 
adherence scale (F [1, 282] = 3.05, p = .08, η2= .01) was not statistically significant and 
indicated there was no difference between groups in parental adherence to ADHD 





Table 6     
Covariates for MANCOVA 
Covariate Scale F p η2 
Parent’s Race Risk 8.24 .004 .03 
 Differential 5.67 .02 .02 
Parent’s Gender Benefits 9.18 .003 .03 
Income Benefits 7.49 .007 .03 




Adherence  16.51 .001 .06 
 
Table 7 
Step-Down Analysis for Dependent Variables 
________________________________________________________________________ 
                                   Met PCMH 
Scale                              Criteria                           n                 M                SD              F             p           η2 
 
Benefits scale 3.55 .01 
No 267 17.51 3.81 
Yes 27 19.33 3.56 
Risk scale 2.74 .01 
No 267 16.96 4.00 
Yes 27 15.74 4.65 
Differential scale 7.68 .006 .03 
No 267 0.56 4.80 
Yes 27 3.59 5.48 
Adherence scale 
No 267 5.79 2.13 3.05   .01 






This study surveyed 294 parents of children diagnosed with ADHD to determine 
the impact of PCMHs on (a) parental beliefs about ADHD medication, and (b) parental 
adherence to ADHD medication.  The results demonstrated that there was a significant 
difference between the PCMH and non-PCMH groups for the differential scale, which 
assessed parental beliefs about the benefits versus risks of ADHD medication when 
controlling for parent’s race, gender, income, and personally having taken ADHD 
medication.  The PCMH group scored higher in their beliefs that the benefits outweighed 
the risks for ADHD medication.  However, no statistically significant results were found 
for the benefits or risks scales.  No statistically significant results were found for the 
adherence scale when controlling for the covariates, which indicated there were no 
differences in parental adherence to ADHD medication between the groups.  
Additionally, parents in the PCMH group had higher incomes and more had personally 
taken ADHD mediation compared to the non-PCMH group.  In the final chapter, I 
compare these findings to the literature draw conclusions and implications, and offer a 





Chapter 5: Discussion, Recommendations, and Conclusion 
The purpose of this quantitative study was to determine if PCMH's have a 
significant impact on parental beliefs about ADHD medication and parental ADHD 
medication adherence.  ADHD costs billions of dollars for the healthcare and educational 
systems and previous attempts to reduce these costs and increase ADHD medication 
adherence have not been successful.  A MANCOVA was used to analyze the data, with 
one variable being PCMH (Yes, No) and two dependent variables, beliefs (benefits, risks, 
differential) and adherence.  Parent’s race, parent’s gender, parent’s income, and whether 
the parent had personally taken ADHD medication were the four covariates included in 
the MANCOVA. 
The results demonstrated that the PCMH group scored higher in their beliefs that 
the benefits outweigh the risks of ADHD medication.  However, there were no significant 
differences between the PCMH and non-PCMH groups on the individual beliefs scales 
(benefits/risks) and the adherence scale.  It is important to note that even though the 
individual risk scale was not significant, the PCMH components are not designed to 
minimize the risks of medication.  The PCMH components are designed to help parents 
better understand ADHD medication for their children, in spite of the associated 
medication risks.  
Interpretation of the Findings 
Parental Beliefs, Medication Adherence, and Patient-Centered Medical Home Use 
This study did not support the literature that indicates positive parental beliefs are 




Fernandez (2013) found that positive parental beliefs about medication were associated 
with the acceptance of pharmacologic treatment options for their children.  Ferrin and 
Taylor (2011) and Pillow et al. (2014) reported parental beliefs and attitudes around 
medication were correlated with parent’s willingness to adhere to medication treatment 
for their children.  In addition, Toomey et al. (2012) found that parents who believed that 
ADHD medication had bad side effects, who were concerned about the long-term effects 
of ADHD medication, and who preferred counseling over medication were more likely to 
discontinue medication use.  Because PCMHs are designed to improve health outcomes 
(Adamson, 2011), increase family-based care, enhance medication decision-making 
(PCPCC, 2012), and reduce unmet needs through the coordination of care (Boudreau et 
al., 2014), it was hypothesized that this study would demonstrate higher parental 
adherence to ADHD medication in the PCMH group.  However, no significant 
differences in adherence were found between the PCMH and non-PCMH groups even 
though the PCMH group had higher benefits versus risks belief scores on the differential 
scale.  These higher belief scores may be attributed to specific PCMH attributes such as 
more time provided for medication education and medical provider relationship 
development.  The results may also be due to the PCMH model in general which 
emphasizes the treatment of the patient as a whole, and takes into account culture, social 
determinants, and the coordination of both behavioral and physical health needs (De 
Vries et al., 2012).  However, additional research is required to better determine how the 




Strecher et al. (1986) reported that self-efficacy is associated with a person’s 
beliefs in their ability to accomplish particular behaviors.  This assertion may have played 
a role in why the higher belief scores in the PCMH group did not translate into 
significantly higher adherence scores in the PCMH group.  Barriers not addressed in this 
study such as transportation (Brown & Bussell, 2011), medication costs (Billimek & 
August, 2014), and medication side effects (Singh et al., 2010; Toomey et al., 2012) have 
been reported to impact medication adherence and are associated with parental self-
efficacy.  Self-efficacy was not evaluated in this study and further research would be 
required to determine what barriers interfere with the conversion of positive parental 
beliefs about ADHD medication into increased ADHD medication adherence in the 
PCMH group.  
Medication Adherence and Persistence 
Some of the most noteworthy information gleaned from this data is the length of 
medication adherence, which was over two years.  The average age that children received 
their first prescription in this research was 6.64 years old, and the average age of children 
at the time of the study was 9.04 years old.  This is contradictory to the literature, which 
reports high ADHD medication discontinuation rates within the first 30 to 60 days of 
medication initiation.  Toomey et al. (2012) reported 42% of children discontinued 
medication within 30 days and only 4% continued taking their medication after 6 months.  
Raman et al. (2015) reported only 35% of children persisted with medication, even with a 
30-day grace period.  Avisar and Lavie-Ajayi (2014) found out of a sample of 14, only 




and adults by Pottegård et al. (2015), fewer than 13% received a second medication refill.  
Thus, it is hypothesized that parent report of medication adherence and persistence may 
have been inflated as a result of response bias from the desire to provide a socially 
desirable answer.  The relatively high education level of the sample could also explain 
the inflated adherence rates of both groups.  Education level is associated with SES and 
has been linked to adherence rates (Noble et al., 2015).  Although the percentage of 
parents with a Bachelor’s degree or higher in the PCMH group (55.6%) was larger than 
that of the non-PCMH group (39.3%), these percentages represented the majority of 
parents in each group, and thus may explain the unusually high medication adherence rate 
in the study overall.  A less educated sample may have yielded different results. 
Previous Parental Experience with Attention-Deficit/Hyperactivity Disorder 
Medication 
Hamrin et al. (2010) and Post et al. (2002) reported that parents who had 
personally taken ADHD medication are influenced by their experience with treatment, 
and this is associated with their acceptance of medication for their children.  Hamrin et al. 
reported this acceptability of ADHD medication can be attributed to the parent’s ability 
to set expectations for their children’s medication use.  In this study, parents in the 
PCMH group scored higher in their beliefs that the benefits outweighed the risks of 
ADHD medication, and 22.2% of them had also personally taken ADHD medication.  
However, 30.1% of parents in the non-PCMH group had personally taken ADHD 




with psychotropic medication may positively impact their beliefs about ADHD 
medication. 
Income, Race, and Gender 
SES and race are reported to be contributors to medication beliefs, adherence 
(August & Billimek, 2015; Brown & Bussell, 2011; Bussing et al., 2003), and PCMH 
attainment (Adams et al., 2013; Knapp et al., 2012; Knapp et al., 2013).  Bussing et al. 
reported that White parents with higher SES had greater access to larger networks and 
healthcare providers from whom to seek advice.  According to Brown and Bussell, those 
with low SES have decreased access to healthcare.  Adams et al. (2013) reported children 
with lower income and who were minorities were less likely to have a PCMH.  Knapp et 
al., (2012) found that White children were almost twice as likely to have a PCMH than 
ethnically diverse children.  Parents in this study were mostly White in both the PCMH 
and non-PCMH groups, although 59.2% of the parents in the PCMH group had incomes 
ranging from $50,001 to over $100,000 and 50.7% of the parents had incomes ranging 
between $0 and $50,000.  The fact that parents in the PCMH group were both White and 
had more reported incomes in the higher range is in line with the literature that indicates 
PCMH status is associated with SES and ethnicity.   
In this study, race was a significant covariate for the differential and risks 
scales.  The data showed that Whites had a higher differential scale score than non- 
Whites and non-Whites had a higher risk score.  This demonstrated that there were racial 
differences related to parental beliefs about ADHD medication and showed non-White 




al. (2013) found that Whites were more likely to take ADHD medication than non-Whites 
and may account for why  Whites in this study scored higher in their beliefs about the 
benefits of ADHD medication. 
Income was a significant covariate for the benefits and adherence scales.  Parents 
who reported their income to be between $75,001 and $100,000 had a higher benefits 
scale score, and parents who reported their income to be between $25,001 and $50,000 
had a higher adherence scale score.  This is counterintuitive because the literature 
suggests more positive beliefs related to the benefits of medication are correlated with 
greater adherence to medication.  It is possible that there were other barriers to adherence 
for parents in the higher income group that were not examined in this study.  
Gender was a significant covariate for the benefits scale. The benefits scale score 
was higher for male parents than for female parents, although male parents represented 
fewer than 29% of the total sample.  This research did not examine gender-related 
differences in beliefs about ADHD medication, and it is not clear why male parents had 
higher benefits-related beliefs.  However, further exploration of parental gender 
differences in beliefs about ADHD medication may be an opportunity for future research. 
Theoretical Framework 
The study results did not support the theoretical framework.  The TPB asserts that 
a person’s beliefs and attitudes impact their behavioral intention, and behavioral intention 
influences the targeted behavior.  In this study, the targeted behavior was parental 
adherence to ADHD medication.  Although a significant difference in parental beliefs 




difference in parental adherence to ADHD medication between groups.  Therefore, 
positive parental beliefs and attitudes about ADHD medication did not translate into the 
performance of the intended behavior, which was adherence to prescribed ADHD 
medication.  This lack of support of the TPB may be the result of the barriers reported 
above such as poor self-efficacy, low SES, and medication side effects, although the 
exact reasons are not clear from this research.  It is also possible that beliefs must meet a 
certain threshold before they are able to change a person’s behavior, which is not a part 
of the TPB and would require further study. 
The UTB (Jaccard, Dodge, & Dittus, 2002) may be an alternate theory to explain 
why the first hypothesis regarding parental beliefs about ADHD medication was 
supported and the second hypothesis regarding parental adherence was not.  This theory 
has been applied to previous research related to medication nonadherence and posits that 
although a person’s intentions are influenced to perform a particular behavior, other 
factors and barriers can impact the actual occurrence of that behavior.  Further research 
would be required to determine parental reasons for nonadherence in this population. 
Limitations 
Medication Adherence Rates and Survey Methodology 
A factor that may have played a role in the unusually high parental adherence to 
ADHD medication in the study is the use of a survey to determine patient adherence.  As 
reported in the literature, surveys have inherent flaws, such as self-report bias and social 
desirability bias (Voils et al., 2011).  In addition, adherence is a difficult behavior to 




advice.  While there is no gold standard for measuring medication adherence, a more 
effective method is through the analysis of pharmacy claims data, which reports 
prescription refill rates.  This method was utilized by Pottegård et al. (2015) who found 
that fewer than 13% of prescriptions were refilled a second time.  The use of pharmacy 
claims data may have yielded lower parental adherence/persistence rates overall in this 
study and revealed differences between the two groups due to more accurate 
measurement.  Future research should be done with pharmacy claims data to accurately 
measure medication adherence.  
Patient-Centered Medical Home Group Assignment 
For parents to be considered to have a PCMH, their responses to all 12 of PCMH-
related survey questions had to match those on Table 3.  If even one of the responses did 
not meet the criteria, the parent could not be included in the PCMH group.  We know 
from the literature that PCMH component execution is inconsistent (Alexander & Bae, 
2012; Richmond & Berry, 2012) and is dependent on factors such as insurance 
reimbursement for components like assistance with referrals and coordination with other 
service providers, and office staff to deliver the component services.  Several researchers 
contend that as a result of poor provider reimbursement for several of the PCMH 
components; such as referral to a specialist, and assistance with medication management 
(Antonelli & Antonelli, 2004; Bodenheimer, 2006; Mcallister,et al., 2009), some 
providers limit the number of non-reimbursable services they provide (White, 2002) thus 




Miller et al. (2015) reported that having all five PCMH components present is 
critical to the effectiveness of PCMHs, and if just one of the five components is missing, 
there is a reduction in the effectiveness of the PCMH for children with special health care 
needs.  Richmond and Berry (2012) asserted approximately only 57% of children with 
special health care needs received all of the services associated with the five components 
of PCMHs, which indicates a significant number of these children do not fully realize the 
PCMH benefit.  The USDHHS; MCHB (2013) also reported only 43% of children with a 
PCMH achieved the full complement of services associated with coordinated and 
comprehensive care.   The reasons attributed to these disparities in service delivery were 
largely attributed to insurance reimbursement for the PCMH components (USDHHS; 
MCHB, 2013) as well as poor execution of the components (Alexander & Bae, 2012).   
In this study, approximately 68% of parents reported they received assistance with 
coordinating care, just over 61% reported their healthcare provider spent enough time 
with them, close to 57% indicated they were able to get a non-family member interpret 
for them, around 52% reported they were satisfied with communication between 
providers, and getting a referral was not a problem, and less than 47% of parents reported 
they were satisfied with communication between providers, school, and other programs.  
Thus, it may be more realistic to consider a change in some of the PCMH criteria 
response requirements to also accept “usually” along with “always” to better reflect the 
real-world experiences of patients with a PCMH when utilizing the survey for research 
group assignment.  In the meantime, Medicaid and other healthcare insurers have moved 




& Thomas, 2012), including the time spent to provide assistance with referrals and 
coordination with other providers, both of which demonstrated low frequency in 
participant reported PCMH criteria in this study. 
Disparate Group Sizes 
The small number of participants in the PCMH group (n = 27); approximately 9% 
of the total sample, may have had an impact on the study outcomes and impact external 
validity.  The NCQA (2014) reported approximately 10% of primary care practices are 
PCMHs and close to 10% of parents surveyed in this study met the PCMH criteria to be 
included in the PCMH group.  Statistical power may also be impacted by the small 
number of participants in the PCMH group and decrease the strength of the results.  
Race and Gender 
In this study, almost 74% of the parents were White and over 71% of them were 
female.  This demographic make up can impact the ability to translate the results to the 
general population.  However, research has shown that the majority of children who are 
diagnosed with ADHD between the ages of 5 and 12 are White (Morgan et al., 2013), and 
You et al. (2015) reported that most often mothers are responsible for dispensing 
medication at home.  Non-White parents and males are underrepresented in this study and 
limits the generalizability of the results.   It is important to conduct further research that 
includes a more diverse sample to better understand how PCMHs impact beliefs and 





The first recommendation is the need for a more accurate tool to measure PCMH 
status or to adjust the current PCMH criteria to include “usually” along with “always” as 
an acceptable response to some of the PCMH criteria (Table 3).   This change may more 
accurately reflect shortcomings in current PCMH performance, such as staff shortages to 
assist with referrals or interpretation services for each patient visit.  These shortages are 
not necessarily due to PCMH status but can be the result of limited insurance 
reimbursement of these services.  Further research that relies on confirmed PCMH status, 
via accrediting bodies like NCQA and healthcare data, instead of participant responses to 
the 2007 NSCH PCMH criteria, may elicit different and/or more accurate participant 
group assignment and lead to a more accurate assessment of PCMHs.  This method 
would provide two groups that are more accurately assigned, provide more accurate 
ADHD adherence data, and produce a much larger PCMH group to support more power 
and external validity. 
Research should also evaluate which PCMH components have the greatest impact 
on medication adherence and ways to improve their consistency and execution, and could 
prove to bridge the gap between parental beliefs about the benefits of ADHD medication 
and enhanced targeted behavior execution (adherence).  In this research, 9 of the 12 
PCMH criteria questions had a frequency count of less than 75%, which indicated that 
parents did not report they received these services all of the time.  It may be possible that 
an increased report of these services would contribute to a gain in parental adherence to 




Almost 30% of parents in this study reported they had personally taken ADHD 
medication.  Although this research did not assess if a parent was currently taking 
medication for ADHD, Chronis-Tuscano, Wang, Woods, Strickland, and Stein (2017) 
reported ADHD symptom severity in the parent primarily involved in childcare could 
impact the treatment outcomes of the child.  Therefore, it might be important to conduct 
this research with more fathers to assess if there are differences in their beliefs and 
adherence to ADHD medication. 
Implications 
This study has positive social change implications as it increases what is known 
about PCMHs and how they impact health outcomes.  This research revealed that 
PCMHs impacted parental beliefs about ADHD medication and found that parents in the 
PCMH group scored higher in their beliefs that the benefits outweighed the risks of 
ADHD medication.  This knowledge may be valuable to healthcare professionals as they 
attempt to positively change the health behavior of parents with children with ADHD.  
Practitioners can now concentrate on the identification and elimination of barriers that 
may interrupt the translation of positive beliefs and attitudes about ADHD medication 
into adherence to ADHD medication.  
This research also exposed some of the shortcomings in the use of the 2007 
NSCH PCMH criteria, which has been used in previous literature (Boudreau et al., 2014; 
Knapp et al., 2013; Toomey et al., 2011) to determine PCMH status.  In research where 
the NSCH is utilized, consideration should be given to PCMH criteria changes that allow 




not be a reflection of PCMH provider status.  Lack of provider reimbursement for PCMH 
services was identified in the literature (PCPCC, 2016) as a reason for suboptimal PCMH 
component delivery.  This study supports previous literature in the need for 
reimbursement of all PCMH services, which is required to realize the full health benefits 
of PCMHs (Miller et al., 2015), and may encourage the transformation of healthcare 
delivery as mandated by the Patient Protection and Affordable Care Act.  
There are theoretical implications for this study, as this research increases what is 
known about the theory of planned behavior (Ajzen, 1991) and challenges how beliefs 
influence behavior.  The theory asserts that a person’s intention to perform a particular 
behavior is the result of the motivational influences on that behavior.  It further contends 
the stronger one’s intention to participate in a behavior, the greater the likelihood that the 
behavior will occur. Therefore, when a person has more positive beliefs, the greater 
his/her intention to perform the targeted behavior.   This research demonstrated that 
parents in the PCMH group scored higher in their beliefs about ADHD medication but 
these higher beliefs did not lead to the intended behavior of ADHD medication 
adherence.  Although significant differences were found in beliefs between groups, it is 
possible that there is a belief baseline that must be achieved before behavior is changed.  
The theory does not take into account the existence of barriers that may preclude the 
execution of the desired behavior, such as financial, access to care, and in particular for 
this study, medication side effects and efficacy; which are the two most common reasons 




Changes to healthcare reimbursement via the Centers for Medicare and Medicaid 
and commercial insurers may not only open the door for more widespread delivery of 
these services, but it may also provide the opportunity for healthcare providers to offer 
more patient-centered and comprehensive care that can benefit the patient, the provider, 
and the payor.  These benefits include decreased hospitalizations, increased academic 
performance, improved peer relationships, and better patient treatment adherence.   
Opportunities also exist for further research to examine if PCMHs positively 
impact health beliefs in other disease states and patient populations based on the 
favorable results found in this study.  As healthcare moves from a traditional fee for 
service structure to a value-based system of care, providers are required to measure and 
report patient outcomes to obtain reimbursement (Porter, Larsson, & Lee, 2016).   
Keeping patients healthy is tantamount to successful provider practices and learning how 
PCMHs can help achieve this is essential.   
Conclusion 
This research found that PCMHs positively influenced parental beliefs about 
ADHD medication, although it did not find that PCMHs significantly improved parental 
adherence to ADHD medication.  Further research is needed to determine how PCMHs 
can have a positive impact on parental beliefs about ADHD medication and result in  
improved parental adherence to ADHD medication.  According to the theory of planned 
behavior (Ajzen, 1991), changing health beliefs is the first step to changing health 




changed to result in behavior change, and/or how patient barriers to behavior change can 
be addressed to support positive behavior execution.    
The Patient Protection and Affordable Care Act includes the transformation of 
practitioner practices into PCMHs and the identification of several PCMH components 
with suboptimal frequency provides a great opportunity for accrediting bodies and policy 
makers on which to focus their attention.  This targeted approach may change how 
healthcare is delivered to this population and may assist PCMHs to improve health 
outcomes for children with ADHD.  
 Methods to increase ADHD medication adherence continue to elude practitioners.  
However, additional research that includes a more diverse sample, with certified PCMH 
practices, that also measure PCMH component execution, might demonstrate that 
PCMHs do increase ADHD medication adherence.  Better adherence could decrease the 
detrimental factors associated with ADHD, such as poor academic achievement, poor 
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Appendix A: Demographic Questionnaire 
 
1. Which category below includes your age? 
a. 18 -29 years old 
b. 30 – 39 years old 
c. 40 – 49 years old 
d. 50 – 59 years old 
e. 60 years old or older 
 
2. Which best describes your race? 
a. White or Caucasian 
b. Black or African American 
c. Native American or Alaska Native 
d. Asian 
e. Hispanic or Latin American 
f. Other race not described here 
 
3. Which best describes your gender? 
a. Male 
b. Female 
4. Which best describes your income? 
a. $0 - $25,000 
b. 25,001 - $50,000 
c. $50,001 – 75,000 
d. $75,001 - $100,000 
e. More than $100,000 
5. Which best describes your education? 
a. Did not complete high school 
b. GED or high school diploma 
c. Some college 
d. Bachelors degree or higher 







7.  Please indicate the state that you live in 
 
• Alabama  
• Alaska  
• Arizona  
• Arkansas  
• California  
• Colorado  
• Connecticut  
• Delaware 
• District of Columbia  
• Florida  
• Georgia  
• Hawaii  
• Idaho  
• Illinois 
• Indiana  
• Iowa  
• Kansas  
• Kentucky  
• Louisiana  
• Maine  
• Maryland  
• Massachusetts  
• Michigan  
• Minnesota  
• Mississippi  
• Missouri  
• Montana 
• Nebraska  
• Nevada  
• New Hampshire  
• New Jersey  
• New Mexico  
• New York  
• North Carolina  
• North Dakota  
• Ohio  
• Oklahoma  





• Rhode Island  
• South Carolina  
• South Dakota  
• Tennessee  
• Texas  
• Utah  
• Vermont  
• Virginia  
• Washington  
• West Virginia  




































Appendix C: Permission to Use BMQ 
Dear Sydney  
Thank for your interest in the Beliefs about Medicines Questionnaire (BMQ) in your 
research. We ask all potential users to sign up to our standard conditions for use of the 
questionnaires.  
These conditions are found on the attached CONDTIONS form. They are not designed to 
restrict your research with the questionnaire or your rights to publish your findings. 
Rather, they are designed to: 
-              Preserve the integrity of the questionnaire 
-              Promote uniformity of analysis and presentation (to facilitate comparison of 
findings across studies) 
-              Ensure that you are using a valid and up-to date version of any disease specific 
BMQ 
If you agree to these conditions then please arrange for the Principal Investigator on your 
study to sign the form and return it by email. Permission to use the questionnaire is 
automatic on receipt on the signed form.  
Please let me know if you require further information. 
Best wishes 
Penny 
Penny Weller  
BSc MSc Health Psychology 
Research Administrator, Centre for Behavioural Medicine 
UCL School of Pharmacy 
Research department of Practice and Policy 
BMA/Tavistock House, Tavistock Square 
London WC1H 9JP 
Email: p.weller@ucl.ac.uk,   




















Appendix E: Scatterplots 
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